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1 Introduction  
1.1 The Neuromuscular Junction  
The transduction of signals between neurons or from neurons to other target cells depends on 
structurally elaborate, asymmetric cell­cell­contacts termed synapses. The process of synapse 
formation, synaptogenesis, is highly complex. It involves correct guidance of neurons to their targets 
and the establishment of specialized structures at the synaptic membranes. Synapses are most 
abundant in the central nervous system (CNS). Nonetheless fundamental knowledge on 
synaptogenesis has been gained from studying a synapse in the peripheral nervous system: The 
neuromuscular junction (NMJ), which mediates signal transduction from motor neurons to muscle 
cells. Compared to synaptic sites in the CNS the NMJ is larger in size and more easily accessible 
(reviewed in (Sanes and Lichtman, 2001)) making it a particularly favorable model system.  
1.1.1 NMJ Structure  
Figure 1a and b depict the ultrastructure of a mature rodent neuromuscular synapse. The motor 
nerve terminal is completely insulated by a peripheral Schwann cell except for the area, which 
contacts the muscle fiber. This part of the neuronal cell membrane is termed presynaptic membrane. 
It opposes the postsynaptic membrane of the muscle cell that is invaginated in adult muscle forming 
postjunctional folds. In between the two membranes, in the so called synaptic cleft, the synaptic 
basal lamina is located, which is composed of extracellular matrix proteins. When a stimulus arrives 
at the motor nerve terminal, it induces fusion of acetylcholine (ACh)­containing vesicles with the 
presynaptic membrane. ACh molecules are released into the synaptic cleft and bind to acetylcholine 
receptors (AChRs) situated at the crests of the junctional folds (Wu et al.).  
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Figure 1| a| Electron Micrograph of a Mature Rodent NMJ EM image courtesy of Dr J. Sanes, Harvard University, USA., 
from (Wu et al.)) |b | The Structure of a Mature Vertebrate NMJ Schematic drawing adapted from (Sanes and Lichtman, 
2001). N… motor neuron, SC… Schwann cell, SBL… synaptic basal lamina, M… muscle fiber, *… ACh­containing vesicles, 
postsynaptic membrane marked in red… AChR clusters | c| Postnatal Maturation of the NMJ Schematic drawing adapted 
from (Sanes and Lichtman, 2001).P0… postnatal day 0, P30… postnatal day 30  
1.1.2 NMJ Formation  
NMJ formation is a complex process that requires a series of coordinated interactions between 
motor nerves and muscle fibers. It is preceded by the differentiation of muscle precursor cells 
(myoblasts) into myotubes and eventually myofibers starting around embryonic day 12­14 (E12­14) 
(Ontell and Kozeka, 1984). As soon as myotubes have formed, they begin to express AChR subunits α, 
β, γ and δ, assemble fetal AChR pentamers (α2βγδ) and insert them into the membrane. The AChR 
pentamers aggregate in the central region of myofibers (Bevan and Steinbach, 1977). This 
‘prepatterning’ is thought to be nerve­independent as it occurs prior to the arrival of motor nerve 
axons (Lin et al., 2001; Yang et al., 2001) and is also observed in mice lacking phrenic or motor nerves 
(Yang et al., 2000). Motor neuron growth cones subsequently contact muscle fibers around E13. It 
has been found that motor neurons stray from central regions of myofibers upon lack of 
prepatterned clusters (DeChiara et al., 1996; Jing et al., 2009; Lin et al., 2001; Yang et al., 2001; Zhang 
et al., 2004). This suggests that aneural AChRs clusters, probably not by themselves but by so far 
unknown factors, guide normal motor axon pathway finding (reviewed by (Wu et al.)).  
Motor neuron attachment establishes one synaptic site per myofiber, which is often innervated by 
several motor axons at the beginning (reviewed by (Lichtman and Colman, 2000)). At the synaptic 
site AChR clusters become stabilized or new clusters are aggregated whereas other pre­existing 
clusters diffuse until E18.5 ((Lin et al., 2001; Vock et al., 2008; Yang et al., 2001)). During postnatal 
NMJ maturation the postsynaptic membrane forms invaginations and AChR clusters are 
concentrated at the crests of the resulting so­called postjunctional folds (Figure 1c). These folds are 
commonly described as structurally resembling pretzels if viewed from above (Figure 2).  
 
b 
P0 
P30 
c a 
Dr. J. Sanes 
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Figure 2| The NMJ of an Adult Mouse Image from (Kummer et al., 2004). 
In parallel to pretzel­formation, multiple innervations are reduced to only one motor neuron contact 
per synapse within two weeks after birth (reviewed by (Lichtman and Colman, 2000)). ACh­induced 
muscle activity decreases expression of AChR subunit γ (Duclert and Changeux, 1995) in favour of 
AChR subunit ε, which replaces subunit γ in AChR pentamers. Thus the fetal form of AChR, AChRγ, is 
exchanged with adult AChRε on the cell surface. The two AChR subtypes differ in their functional 
properties (Mishina et al., 1986) and both have been shown to be essential for normal synaptic 
development and function (Missias et al., 1997; Takahashi et al., 2002; Witzemann et al., 1996). 
1.1.3 Agrin/ LRP4/ MuSK­Signaling  
Elucidation of the molecular factors and signaling pathways controlling neuronal AChR clustering and 
NMJ formation was originally hampered by the fact that the specific activity of synaptic components, 
i.e. the moles per gram of tissue, is low in muscle. But investigation of the ray, Torpedo californica, 
boosted research on NMJ formation. The electric organ of this sea dweller can be considered a 
hypertrophied NMJ, from which the contractile components have been lost (Cartaud et al., 2000). 
Thus, the specific activity of AChRs is ~1000 times higher than in muscle (Berg et al., 1972). Many 
central postsynaptic components, such as AChRs but also MuSK, agrin and rapsyn, which will be 
discussed in the following, were first isolated from Torpedo electric organs (Cartaud et al., 2000).  
The extracellular matrix protein agrin was identified as key activator of postsynaptic differentiation 
already in 1989 (McMahan, 1990; Wallace, 1989). Motor nerve terminals release agrin, which 
associates with the synaptic basal lamina. It binds the postsynaptic transmembrane receptor protein 
LRP4 that clusters and activates a receptor tyrosine kinase termed muscle­specific kinase (MuSK) on 
the myobfiber membrane. The cytoplasmic membrane­associated muscle protein Dok7 supports this 
activation process. Through association with the cytoplasmic linker protein rapsyn and several not 
completely elucidated signaling processes, activated MuSK induces clustering of AChRs and other 
postsynaptic molecules and thus the formation of the NMJ (Figure 3).  
Kummer et al., 2004 
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Figure 3| Agrin/ LRP4/ MuSK­Signaling Schematic drawing adapted from (Burden, ; Ghazanfari et al., ; Wu et al.). Motor 
neurons release agrin, which binds LRP4 and stimulates MuSK autophosphorylation and activation. (LRP4 has been shown 
to directly interact with MuSK. It is supposed that interaction is dependent on the most N­terminal Ig domain of MuSK as 
indicated by dotted arrows.) Autophosphorylation of MuSK is supported by Dok7 through binding of the Dok7 PTB­domain 
to MuSK and Dok7 PH­PTB dimerization. Activated MuSK induces AChR clustering through a mechanism that is not fully 
understood. The process is dependent on rapsyn, but it is unclear whether MuSK directly interacts with rapsyn or via a so 
far unknown hypothetical protein RATL (indicated by the dashed outline). Ig… Ig domain, C6… cysteine­rich domain, TM… 
transmembrane domain, JM… juxtamembrane domain, TK… kinase domain, P… phosphorylation, PM… plasma membrane, 
PH…. PH­domain, PTB… PTB­domain. For details see chapters 1.1.3 to 1.6. 
1.2 Neuromuscular Diseases  
Severe impairment of NMJ formation or function, resulting in muscle weakness, is causative for 
congenital myasthenic syndromes (CMS). Mutations leading to CMS have been identified in several 
NMJ components including all subunits of the AChR, MuSK, rapsyn and Dok7 (Beeson et al., 2006; 
Chevessier et al., 2004; Engel et al., 2003; Sine and Engel, 2006). Defects in AChR subunits commonly 
change the expression or the kinetic properties of the AChR pentamers. In contrast, patients with 
Dok7 mutations often exhibit abnormal NMJ size or structure (as reviewed in (Engel et al.)). Whereas 
these types of muscle weaknesses have a genetic background others constitute autoimmune 
diseases. In acquired myasthenia gravis (MG), patients produce antibodies against NMJ components. 
About 85 % of MG patients test positive for AChR antibodies (Meriggioli, 2009), which upon binding 
to postsynaptic AChRs lead to focal destruction of the postsynaptic membrane (Meriggioli and 
Sanders, 2009). Of the remaining 15 % about 70 % are positive for antibodies against MuSK (Vincent 
et al., 2008). The pathogenicity of MuSK antibodies is not completely understood, but injection of 
anti­MuSK­positive patient IgG has been shown to cause depletion of postsynaptic MuSK and 
disassembly of AChR clusters in mice (Cole et al.). The remaining 30% do not test positive for either 
of the two antibodies and are thus termed seronegative. However, they might express antibodies 
against other postsynaptic components.  
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1.3 Agrin  
Agrin is a large heparin proteoglycan that is expressed in different isoforms by myotubes, Schwann 
cells and motor neurons at the NMJ. It was found in 1989 to be capable of inducing aggregation of 
AChRs as well as other components of the postsynaptic apparatus on cultured myotubes (Wallace, 
1989). In ‘The agrin hypothesis’ McMahan suggested that agrin is the key signal in nerve­dependent 
postsynaptic differentiation (McMahan, 1990). This hypothesis was supported by the findings that 
postsynaptic differentiation is strongly impaired in agrin­deficient mice (Gautam et al., 1996) and 
that introduction of agrin into denervated muscle induces the formation of an almost complete 
postsynaptic apparatus (Bezakova and Lomo, 2001; Cohen et al., 1997; Meier et al., 1997). Agrin has 
three splice sites x, y and z. Alternative splicing generates isoforms containing one or more splice 
inserts of different lengths at the x, y and z sites. For instance, Agrin12,8,0 comprises a 12 amino acid 
(aa) insert at the x site, an 8 aa insert at the y and no insert at the z­site. Neuron specific isoforms 
have a 4 aa insert at the y splicing position and an 8, 11 or 19 aa insert at the z position. The insert at 
the x position is not biologically relevant. Inserts at the z site are characteristic for neuronal isoforms 
and are not found in agrin forms expressed in other tissues. Thus neuronal agrin is commonly termed 
z+ agrin (Ferns et al., 1993). That neuronal z+ agrin but not the muscle­derived isoform, known as z­ 
agrin, is essential for NMJ formation was demonstrated via z+ agrin knockout mice. These exhibited 
similarly defective NMJ formation as complete agrin deletion mutants (Burgess et al., 1999). 
Compared to muscle­derived agrin, the neuronal isoform z+ agrin was shown to be approximately 
1000 times more potent in inducing AChR clusters (Gesemann et al., 1995). On the basis of these 
findings agrin was initially proposed to be required for AChR clustering. However, AChR 
prepatterning at E13­14 is normal in agrin­deficient mice implicating that the protein is dispensable 
for the process. But upon lack of agrin, motor neurons are unable to form stable synaptic contacts 
with the prepatterned clusters leading to excessive axonal branching and dispersion of primary AChR 
clusters (Lin et al., 2001; Yang et al., 2001). Consequently it was proposed that agrin acts (in complex 
with MuSK) as component of a neuronal stop signal (Dimitropoulou and Bixby, 2005) capable of 
stabilizing neuron­muscle interaction, inhibiting AChR dispersion (Witzemann, 2006) and regulating 
axonal branching (Campagna et al., 1995; Gautam et al., 1996).  
1.4 MuSK  
Muscle­specific kinase (MuSK), a 100 kDa transmembrane protein belonging to the RTK superfamily, 
was originally identified due to its selective expression in the electric organ of the ray, Torpedo 
californica (Jennings et al., 1993) and in mammalian muscle (Valenzuela et al., 1995).  
1.4.1 The Receptor Tyrosine Kinase Superfamily  
RTKs are a diverse family of cell surface receptors, which are involved in major signaling pathways 
regulating proliferation, differentiation, migration and metabolic changes (Schlessinger and Ullrich, 
1992). The superfamily includes receptors for insulin, epidermal growth factor (EGF), fibroblast 
growth factor (FGF) and platelet­derived growth factor (PDGF). Structurally, RTKs comprise an 
extracellular portion, which often contains various globular domains including immunoglobulin (Ig)­
like, EGF­like or cysteine­rich domains, for instance. The transmembrane helix is followed by a 
juxtamembrane region, a tyrosine kinase domain and a C­terminal portion. Most RTKs consist of a 
single polypeptide chain and are monomeric in the absence of their cognate ligand. Upon binding of 
a ligand to the extracellular portion the receptors oligomerize, which facilitates interaction of the 
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intracellular kinase domains and leads to trans­autophosphorylation. Commonly, tyrosines in the 
activation loop (A loop) within the kinase domain are phosphorylated first, stimulating kinase 
activity. As a consequence, tyrosine residues situated in the juxtamembrane region, the kinase 
domain and the C­terminal region become phosphorylated. This generates docking sites for 
downstream signaling proteins with phosphotyrosine­binding modules such as SH2 domains and 
phosphotyrosine­binding (PTB) domains (Kuriyan and Cowburn, 1997) (reviewed in (Hubbard and Till, 
2000)).  
1.4.2 MuSK Structure and Function  
MuSK comprises four immunoglobulin­like domains and a cysteine­rich domain in the extracellular 
region. The transmembrane domain is followed by a juxtamembrane domain and a catalytic tyrosine 
kinase domain (Ghazanfari et al.) (Figure 4). De Chiara et al. found that although AChR expression is 
normal in Musk ­/­ mice they are unable to form NMJs and die at birth due to respiratory failure 
(DeChiara et al., 1996). Consistently, Glass et al. reported that neuronal agrin can not induce AChR 
clustering in Musk ­/­ muscle fibers (Glass et al., 1996). Both findings indicated that MuSK acts as 
receptor for agrin. But despite intensive studies, direct interaction of MuSK and agrin could not be 
demonstrated. Eventually another transmembrane muscle protein, LRP4, was reported to directly 
interact with agrin and MuSK and was established as agrin receptor (Kim et al., 2008; Zhang et al., 
2008). MuSK was shown not only to be required for agrin­responsiveness but also for agrin­
independent AChR­prepatterning. Embryos lacking MuSK form neither aneural clusters nor agrin­
induced clusters (DeChiara et al., 1996; Lin et al., 2001); (Yang et al., 2001).  
 
Figure 4| Domain structure of MuSK Schematic drawing adapted from (Ghazanfari et al.). Ig… Ig domain, C6… cysteine­rich 
domain, TM… transmembrane domain, JM… juxtamembrane domain, TK… kinase domain, N… N­terminus, C… C­terminus. 
1.4.3 MuSK Regulation  
MuSK expression is upregulated upon differentiation of muscle precursor cells and downregulated 
when muscle fibers become innervated (Tang et al., 2006). It is integrated into the myotube 
membrane where it probably forms complexes with LRP4 prior to innervation (Kim et al., 2008). 
Upon arrival of a neuronal outgrowth and release of agrin, which binds LRP4, MuSK undergoes 
autophosphorylation at tyrosine (Tyr) residues and induces AChR clustering through signaling 
mechanisms that haven’t been completely elucidated so far. Among other proteins, Dok7 (Okada et 
al., 2006) and Tid1 (Linnoila et al., 2008) have been reported to interact with activated MuSK and 
regulate MuSK function. Moreover, activation­dependent internalization of MuSK regulated by direct 
interation with the ATPase N­ethylmaleimide sensitive fusion protein (NSF) was observed to be 
required for AChR clustering (Zhu et al., 2008). The internalization process might further be 
influenced by ubiquitination of endocytosed MuSK. MuSK directly interacts with PDZ domain­
containing RING finger 3 (PDZRN3), a synapse­associated E3 ubiquitin ligase, which catalyzes MuSK 
ubiquitination. MuSK activation enhances both interaction and ubiquitination and leads to PDZRN3­
dependent downregulation of MuSK cell surface levels. Inhibitor experiments suggested that this 
reduction of MuSK surface expression is achieved by lysosomal degradation of MuSK (Lu et al., 
2007b).  
Ig1 Ig2 Ig3 C6 Ig4 TM JM TK N C 
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1.4.4 MuSK Downstream Signaling  
As described, AChR clustering is dependent on MuSK as well as on rapsyn, a 43 kDa membrane­
associated cytoplasmic protein (Sanes and Lichtman, 2001), which interacts directly with AChR 
subunits (Froehner et al., 1990; Gautam et al., 1995; Huebsch and Maimone, 2003; Maimone and 
Merlie, 1993) and shows perfect co­localization with AChRs in adult NMJs (LaRochelle and Froehner, 
1986; Noakes et al., 1993). However, the mechanism of MuSK­rapsyn signaling is still a matter of 
debate. Studies in QT­6 fibroblasts indicated that the extracellular domain of MuSK interacts with 
rapsyn via a rapsyn­associated transmembrane linker protein (RATL), which is expressed in muscle 
cells and fibroblasts (Apel et al., 1997; Zhou et al., 1999). In contrast, Antolik et al., reported agrin­
independent direct interaction of a large fragment of the cytoplasmic domain of MuSK with rapsyn 
upon coexpression in COS­7 cells. In addition to rapsyn, small GTPases appear to influence AChR 
localization. Rho­GTPases Rac and Cdc42 are known as regulators of actin cytoskeleton 
reorganization and have been shown to be activated by agrin and to be essential for AChR clustering 
(Weston et al., 2000). Consistently, it has been demonstrated that actin polymerizes at sites of AChR 
clustering upon agrin­stimulation and that inhibition of this polymerization blocks cluster formation 
(Dai et al., 2000).  
1.5 LRP4  
After its identification, MuSK was soon established as an essential factor in agrin­induced AChR 
clustering. But the molecular basis for agrin/ LRP4/ MuSK­signaling remained elusive since the two 
proteins do not interact directly (Glass et al., 1996). It was suggested that one or more until then 
unknown molecules, termed myotube­associated specificity component (MASC), bridge agrin and 
MuSK. In 2008 two groups reported the identification of a protein called low­density lipoprotein 
receptor (LDLR)­related protein 4 (LRP4) as this long­searched agrin receptor (Kim et al., 2008; Zhang 
et al., 2008).  
LRP4 comprises a large extracellular N­terminal region with multiple EGF repeats and LDLR repeats 
followed by a transmembrane domain and a short intracellular domain, which lacks an identifiable 
catalytic motif (Johnson et al., 2005; Lu et al., 2007a; Tian et al., 2006; Yamaguchi et al., 2006).  
Lrp4 mutant mice suggested that LRP4 is required for the normal development of the lung, kidney 
and ectodermal organs. But it was found that lack of LRP4 also causes severe defects in NMJ 
formation and neonathal lethality as observed for MuSK ­/­ mice (Weatherbee et al., 2006). Further 
analysis revealed that LRP4 is enriched at the NMJ (Zhang et al., 2008). It is barely detectable in 
myoblasts but expression is upregulated upon differentiation and highest in well­differentiated 
myotubes. LRP4 could be demonstrated to be required for agrin­stimulated MuSK activation. Agrin 
failed to induce MuSK phosphorylation in lrp4 mutant myotubes although surface MuSK protein 
expression was normal (Kim et al., 2008). Different binding assays showed that LRP4 directly interacts 
with agrin via its extracellular portion (Zhang et al., 2008) and that LRP4 preferentially binds neuronal 
agrin and exhibits only minimal affinity for non­neural isoforms (Kim et al., 2008; Zhang et al., 2008). 
If expressed in lrp4 mutant myotubes, LRP4/LDLR­chimeric molecules composed of LRP4 extracellular 
and transmembrane and LDLR intracellular domain but not wild­type LDLR could substitute LRP4. 
This indicates that the cytoplasmic domain of LRP4 is dispensable for agrin­responsiveness (Kim et 
al., 2008).  
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It was found that LRP4 self­associates (Kim et al., 2008) and forms a complex with MuSK in an agrin­
independent manner (Kim et al., 2008; Zhang et al., 2008). Agrin binding to LRP4 apparently 
increases this LRP4­MuSK association (Zhang et al., 2008). It has also been proposed that agrin 
induces a conformational change in the preformed complex, which leads to reorientation of adjacent 
MuSK molecules and thereby facilitates trans­phosphorylation (Kim et al., 2008). In earlier studies, 
the most N­terminal Ig­like domain in MuSK has been reported to be essential for agrin­stimulated 
MuSK activation (Stiegler et al., 2006; Zhou et al., 1999). Considering the described findings, this 
domain might be involved in LRP4/MuSK­association and in the suggested conformational 
rearrangement (Kim et al., 2008). However, further structural and biochemical studies are required 
to completely uncover the mechanisms of agrin/ LRP4/ MuSK­signaling.  
1.6 Dok7  
Dok7 is a member of the Dok­family of adaptor proteins that is preferentially expressed in skeletal 
muscle and heart and concentrated postsynaptically at NMJs in mouse skeletal muscle (Okada et al., 
2006). Beeson et al. and Müller et al. demonstrated that recessive mutations at several sites in Dok7 
induce congenital myastenic syndrome (CMS) (Beeson et al., 2006; Muller et al., 2007) indicative of a 
role in muscle activity or NMJ development. Dok7 knockout mice showed that Dok7 is essential for 
NMJ formation (Okada et al., 2006). The mice exhibit a phenotype indistinguishable from that of 
MuSK knockout mice: They are immobile at birth and die shortly afterwards, show inability to 
breathe and a lack of AChR cluster formation (Okada et al., 2006). Forced expression of Dok7 in C2 
myotubes was found to induce MuSK autophosphorylation as well as tyrosine phoshorylation of the 
ß subunit of the AChR complex (AChRß1), which is usually observed upon activation of MuSK. This 
effect was mediated by direct physical interaction of MuSK and Dok7 (Okada et al., 2006). 
The N­terminal portion of Dok7 comprises a pleckstrin­homology (PH) and a phosphotyrosine­binding 
(PTB) domain (Figure 5). Multiple Src homology 2 (SH2) domain target motifs i.e. multiple tyrosine 
phosphorylation sites (Bergamin et al., ; Okada et al., 2006) are located in the extended C­terminal 
region.  
Mutational studies and structural analysis revealed that Dok7 interacts with MuSK via its PTB domain 
dependent on MuSK autophosphorylation. When clustered, MuSK molecules autophosphorylate in 
trans on Tyr553 in the juxtamembrane region and on Tyr750, Tyr745 and Tyr755 in the activation 
loop of the kinase domain (Herbst and Burden, 2000; Watty et al., 2000). Tyr553 is located in a PTB 
domain target motif asparagine­proline­X­tyrosine (NPXY­) motif, the X standing for an optional 
amino acid. Upon phosphorylation, this motif is bound by the PTB domain of Dok7. Dok7 on the one 
hand serves as a substrate, being phosphorylated on Tyr395 and Tyr405 (Hamuro et al., 2008). On 
the other hand, it activates the catalytic activity of MuSK (Inoue et al., 2009; Okada et al., 2006) by 
dimerizing MuSK (Bergamin et al.). Binding of Dok7 to MuSK is followed by PH­PTB dimerization of 
Dok7, which leads to juxtaposition of MuSK kinase domains and facilitates MuSK trans­
autophosphorylation. Inhibition of Dok7 dimerization was shown to largely abolish its activating 
effect on MuSK autophosphorylation (Bergamin et al.). But similar to most other PH­domains in 
phosphotyrosine signaling pathways, also the Dok7 PH­domain rather non­specifically interacts with 
membrane phosphoinositides. Thus the PH­domain of Dok7 appears to serve two roles: it supports 
MuSK dimerization and on the other hand mediates plasma membrane localization via 
phosphoinositide binding (Bergamin et al.).  
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Figure 5| Domain architecture of human Dok7 Schematic drawing adapted from (Bergamin et al.). The positions of the PH­
domain (PH) and the PTB­domain (PTB) and of two phosphorylation sites, Tyr395 (Y395) and Tyr405 (Y405) are indicated. 
N… N­terminus, C… C­terminus.  
1.7 Ubiquitination  
Ubiquitination is an ATP­consuming process, which mediates the post­translational modification of a 
target protein via the covalent attachment of the 76­amino acid protein ubiquitin. The conjugation 
reaction is highly conserved between species, just as ubiquitin (Ub) itself (Schlesinger and Bond, 
1987), and is dependent on the sequential actions of three enzymes (Hershko and Ciechanover, 
1998). In the first step a thiol­ester linkage is formed between the C­terminal glycine residue of Ub 
and the active cysteine (Cys) residue of ubiqutin activating enzyme (E1). This activation reaction is 
driven by the hydrolysis of one ATP to AMP and inorganic diphosphate (PPi). Subsequently the 
ubiquitin molecule is transferred to the cysteinyl group of ubiquitin­conjugating enzyme (E2). 
Mediated by a third enzyme termed ubiquitin ligase (E3), ubiqutin is attached to a target protein via 
an amide (isopeptide) bond between the C­terminal glycine and an optional amino acid residue of 
the target protein (Figure 6). E3 ligases confer specificity to the reaction but are a strongly 
inhomogeneous group of proteins.  
Via the described cascade a single Ub molecule may be linked to a single amino acid residue in a 
target protein. However, the reaction does not only allow such monoubiquitination but can also 
mediate the addition of multiple Ub molecules to different target sites in one protein resulting in 
multi­ubiquitination. Moreover, after its addition to a protein, the ubiquitin molecule itself can be 
targeted by the ubiquitination machinery giving rise to polyubiquitin chains (Figure 7). So far, seven 
Lys residues of Ub, K6, K11, K27, K29, K33, K48 or K63, have been identified that can serve as 
conjugation sites (Peng et al., 2003) (Figure 8). Thus, polyubiquitin chains can not only vary in length, 
meaning in the number of Ub molecules, but also therein, at which lysine residue individual Ub 
molecules are linked together. These differences have been shown to influence polyubiquitination­
associated signaling. Whilst Lys48­linked polyubiquitin chains of at least four molecules have been 
demonstrated to target proteins to proteasomal degradation, Lys63­linked polyubiquitination might 
play a role in DNA damage tolerance (Pickart and Fushman, 2004), signal transduction 
(Mukhopadhyay and Riezman, 2007; Sun and Chen, 2004) and intracellular trafficking of membrane 
proteins (Geetha et al., 2005; Hicke, 1999; Mukhopadhyay and Riezman, 2007). The results of Xu et 
al. suggested that in general all non­Lys63­linked polyubiquitinations induce protein degradation (Xu 
et al., 2009). But Seibenhener at al. and Saeki et al. found that even K63­polyubiquitin chains can 
target proteins to the 26S proteasome (Saeki et al., 2009; Seibenhener et al., 2004). It is thought that 
mono­ as well as polyubiquitination possess non­proteasomal regulatory functions (Hershko and 
Ciechanover, 1998; Pickart, 2001), but so far it has not been possible to clearly decipher the ubiquitin 
code.  
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Figure 6| The Ubiquitination Cascade Schematic drawing adapted from http://faculty.ucr.edu/~karine/research.html, 
available: 2011­02­21, 4.00 p.m.. 
 
Figure 7| Types of Ubiquitination| a| Monoubiquitination| b| Multiple Monoubiquitination| c| Polyubiquitination 
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Figure 8| a| Ubiquitin Amino Acid Sequence The amino acid sequence of human ubiquitin is depicted in the single­letter 
code. The seven Lys residues K6, K11, K27, K29, K33, K48 or K63 have been shown to be used for conjugating individual Ub 
molecules in polyubiquitin chains (shaded in gray) (Peng et al., 2003).| b| Lys48­Polyubiquitination A target protein 
modified at an optional lysine residue Kn with a polyubiquitin chain. In the polyubiquitin chain each Ub molecule (but the 
first in the chain) is linked to a previous Ub molecule via the Lys48 residue (K48) of the previous Ub. 
Considerable efforts have been undertaken to identify factors that regulate whether and at which 
residue a protein is ubiquitinated. It has been suggested that various structural determinants rather 
than a single consensus sequence direct E3 ligases to distinct lysines (reviewed in (Jadhav and 
Wooten, 2009)). 
For instance, protein stretches that are rich in proline (P), glutamate (E), serine (S), and threonine (T) 
and are therefore termed PEST sequences have been described to act as proteolytic recognition 
signals in rapidly degraded proteins (Rogers et al., 1986). Such proteins were found to be 
phosphorylated at Ser and Thr residues within the PEST motif, which preceded ubiquitination and 
stimulated degradation via the ubiquitin­proteasome pathway (Lanker et al., 1996; Willems et al., 
1996; Won and Reed, 1996; Yaglom et al., 1995). Nonetheless there also exist short sequence motifs, 
which mediate protein turnover. A small N­terminal motif termed “destruction box” or “D­box”, 
which comprises nine amino acid residues in the minimal form, regulates ubiquitination of mitotic 
cyclins (Glotzer et al., 1991). In the N­end rule pathway, E3 Ub ligases recognize N­degrons of 
proteins consisting of a destabilizing N­terminal residue and an internal lysine. Upon substrate 
binding, the ligase termed N­recognin catalyzes polyubiquitination of the target protein. As reviewed 
by Jadhav and Wooten (Jadhav and Wooten, 2009), several more such determinants for the 
regulation of ubiquitination have already been described, which illustrates the complexity of the 
process.  
Like phosphorylation, ubiquitination is a reversible posttranslational modification. Whilst Ub ligases 
mediate conjugation of Ub, so called de­ubiquitinating enzymes (DUBs) are capable of removing Ub 
molecules. Longva et al. reported that inhibition of deubiquitination decreased the transport of 
proteins to multi­vesicular bodies, an important step in lysosomal degradation (Longva et al., 2002). 
In contrast J. Alwan et al. argued, that they only observed minor effects on lysosomal degradation 
when deubiquitination was blocked (Alwan et al., 2003). However, ubiquitination creates an 
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additional site for protein­protein interactions (Hicke et al., 2005; Hurley et al., 2006), which in turn 
could be associated with signaling pathways and might be fine­tuned by DUBs.  
1.8 Endocytosis & Ubiquitination  
Endocytosis enables cells to take up fluid, solutes and small particles from the extracellular 
environment. In the first step of this process, substrates get localized at the plasma membrane, 
which can be achieved by binding to cognate receptors, for instance. The membrane consequently 
invaginates forming a ‘bud’. The bud grows until the plasma membrane at its neck is brought close 
enough to fuse and thereby seal off the forming vesicle.  
There exist several types of endocytosis, the best studied among them being clathrin­mediated 
endocytosis (CME), macropinocytosis and caveolar/ raft­dependent endocytosis. Less well known but 
currently of high scientific interest are clathrin­ and caveolin/ raft­independent pathways such as the 
Flottilin­ and the Arf6­pathway (reviewed in (Mercer et al.)).  
Ligand­mediated endocytosis has been described for various cell surface receptors including the 
Insulin receptor (Di Guglielmo et al., 1998) as an early step in the associated signaling pathways. 
Binding of cognate ligand was reported to stimulate targeting of receptors to clathrin­coated 
invaginations, which eventually form clathrin­coated vesicles. The vesicles deliver the ligand­receptor 
complexes to endosomal compartments where sorting processes determine the eventual fate of the 
cargo. The receptors can be retained in the endosome, recycled and transported back to the cell 
membrane or targeted to lysosomal degradation. Two functions have been attributed to ligand­
mediated endocytosis. On the one hand, it is considered a mechanism to downregulate activated cell 
surface receptors. On the other hand, internalization might be required to position receptor at an 
intracellular location to enable it to interact with downstream signaling molecules (reviewed in 
(Ceresa and Schmid, 2000)).  
In yeast, attachment of ubiquitin molecules was found to trigger internalization of transmembrane 
receptors (Galan and Haguenauer­Tsapis, 1997). This prompted researchers to uncover whether a 
comparable mechanism exists in mammalian cells. Studies revealed that indeed several RTKs such as 
EGFR, PDGFR or TrkA undergo ligand­stimulated ubiquitination (Arevalo et al., 2006; Geetha et al., 
2005; Haglund et al., 2003; Huang et al., 2006; Joazeiro et al., 1999). Consistently, ubiquitination has 
been reported to influence the downmodulation of the majority of RTKs (reviewed in (Bache et al., 
2004)). However, it is still unclear whether modification with Ub molecules directly affects 
endocytosis or rather regulates downstream mechanisms. Haglund et al. employed chimeric proteins 
composed of the extracellular and transmembrane portion of EGFR and full­length Ub to study the 
effect of ubiquitination on EGFR internalization (Haglund et al., 2003). The wild­type form of these 
bona fide monoubiquitinated EGFR­Ub chimeras was shown to become elongated by 
polyubiquitination at Ub, whereas an Ub mutant form could not be ubiquitinated further. It could be 
demonstrated that monoubiqutination was sufficient to induce receptor endocytosis, although 
internalization was more pronounced for the wild­type receptor. Indeed, EGFR has been shown via 
quantitative mass­spectrometry to be mono­ as well as polyubiquitinated by Lys63­linked chains 
(Huang et al., 2006). Nonetheless, mutations in EGFR that inhibit ubiquitination do not significantly 
affect its internalization via clathrin­coated pits (Duan et al., 2003; Huang et al., 2007; Sigismund et 
al., 2005). This allows questioning the relevance of this modification. But, as reviewed by Acconcia et 
al. (Acconcia et al., 2009), receptor ubiquitination is apparently regulated by EGF concentration, 
13 
which also seems to influence targeting of the receptor to distinct internalization pathways 
(Sigismund et al., 2005; Woelk et al., 2006). In the respective analyses, ubiquitination was not 
detectable at low EGF doses and EGFR was exclusively internalized via clathrin­mediated endocytosis. 
At high doses, however, EGFR was ubiquitinated and targeted to clathrin­coated vesicles as well as to 
other, clathrin­independent pathways. As CME primarily leads to receptor recycling whereas clathrin­
independent endocytosis preferentially targets EGFR to degradation (Sigismund et al., 2008), it was 
suggested that ubiquitination might, by determining the internalization route, regulate receptor 
downmodulation.  
1.9 Protein Degradation  
Eukaryotic cells possess two major systems for protein degradation: Lysosomes, vesicular cell 
organelles, represent the terminal compartment of endocytic and autophagic pathways (Luzio et al.) 
and account for about 10 ­ 20 % of total protein degradation (Gronostajski et al., 1985). 80 ­ 90 % of 
protein breakdown (Gronostajski et al., 1985) however is catalyzed by the ATP­dependent 26S 
proteasome, a 2000 kDa proteolytic complex (Coux et al., 1996).  
1.9.1 Endosomal­Lysosomal Degradation  
Lysosomes were discovered by Christian de Duve in the 1950s (De Duve et al., 1953; Gianetto and De 
Duve, 1955) and were originally described as vacuolar structures containing various hydrolytic 
enzymes that show optimal performance at an acidic pH (reviewed in (Ciechanover, 2006)). Further 
studies established the lysosome as the last compartment of the lysosomal degradation pathway, 
which accounts for the degradation of exogenous proteins (and their cognate receptors) taken up via 
receptor­mediated endocytosis and pinocytosis or exogenous particles engulfed during phagocytosis. 
Moreover, it catalyzes the breakdown of endogenous proteins and cellular organelles targeted to the 
lysosome via autophagy (reviewed in (Ciechanover, 2006)).  
Extracellular low­density lipoprotein (LDL), for instance, is endocytosed upon binding to its receptor 
on the cell surface. The ligand­receptor complex is transported to the early endosome where the 
ligand dissociates due to the acidic pH in the endosomal lumen. This allows recycling of the receptor 
to the cell surface. In contrast, epidermal growth factor (EGF), another extracellular molecule also 
taken up via receptor­mediated endocytosis, remains bound to its receptor (reviewed in (Luzio et al., 
2007)). Released ligand or the ligand­receptor complex respectively proceeds to late endosomes. 
These are formed from early endosomes, but the responsible mechanism is still a matter of debate. 
Recent live­cell imaging studies suggested that large late endosomal vesicles arise from a dynamic 
early endosome network and undergo a maturation process, in which they lose the small GTPase 
Rab5 and recruit Rab7 (Rink et al., 2005). The resulting late endosomes contain more vesicles in their 
lumen than early endosomes and are thus also termed multivesicular bodies (MVBs) (Luzio et al., 
2007). Several theories exist on how material is subsequently transported from late endosomes to 
lysosomes. However, it was recently demonstrated that fusions of endosomes and lysosomes as well 
as kiss­and­run events, in which endosomal vesicles transiently dock to lysosomes (‘kiss’), release 
material and dissociate again (‘run’), contribute to the mixing of endosomal and lysosomal contents 
(Bright et al., 2005) (Figure 9b).  
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1.9.2 Rab7  
Rab GTPases (‘Ras­related in brain’ (Touchot et al., 1987)) represent a diverse family of regulator 
proteins, which localize to the cytosolic face of intracellular membranes and are central to 
intracellular vesicular transport. Belonging to the Ras superfamily of small GTPases, they switch, like 
other regulatory GTPases, between two conformational states: the GTP­bound, ‘active’ 
conformation, which enables them to recruit and bind effector molecules (Zerial and McBride, 2001) 
and the GDP­bound, ‘inactive’ conformation.  
Rab proteins obviously control distinct membrane transport pathways through localization to distinct 
intracellular membranes and specific binding of effector molecules (reviewed in (Stenmark and 
Olkkonen, 2001)). Rab4a and Rab5a have – among other Rabs ­ been localized to early sorting and 
recycling endosomal compartments (Bucci et al., 1995; Van Der Sluijs et al., 1991). In contrast, Rab7 
has been described as a key regulator of membrane transport from early to late endosomes (Feng et 
al., 1995) and apparently plays a role in the proper aggregation and fusion of late endocytic 
structures, which is required for the biogenesis and maintenance of the lysosomal compartment 
(Bucci et al., 2000).  
When tracking a protein in a cell on its way to degradation a major task is to identify the structures 
and organelles it is transported to. Proteins that are exclusively found in particular cellular areas, also 
referred to as ‘markers’, are helpful tools in such analysis. Due to its specific localization and function 
Rab7 has emerged as such a marker for late endosomal structures. Co­localization with Rab7 
indicates that the protein of interest is situated in endosomal vesicles, which generally transport 
material to the lysosome and thus suggests degradation of the respective protein via the lysosomal 
pathway.  
1.9.3 Proteasomal Degradation  
The 26S proteasome is a proteolytic complex made up of the central 20S proteasome, which 
catalyzes proteolysis and two 19S complexes, which confer substrate specificity (Coux et al., 1996). 
The four stacked rings of the 20S proteasome surround a proteolytic chamber where proteolysis is 
catalyzed by multiple proteolytic sites ­ two chymotrypsin­like, two trypsin­like, two caspase­like sites 
in eukaryotes ­ provided by the central two ß­rings (Figure 9a). Substrates enter through a small 
opening enclosed by the outer two α­rings. Most substrates of the proteasome are first marked by 
covalent modification with ubiquitin molecules by ubiquitinating enzymes (Ciechanover, 1994; 
Goldberg, 1995). This ensures precise and specific regulation of protein turnover. Ubiquitin chains 
are recognized by ubiquitin­binding sites on the 19S complexes. The chains are consequently 
degraded and proteins are unfolded. Both processes are catalyzed by the 19S complexes, which also 
facilitate entering of substrates into the 20S proteasome (reviewed in (Lee and Goldberg, 1998)). 
Protein degradation in the proteasome is highly processive and leads to complete digestion of 
substrates. Thereby it is excluded that large, potentially bioactive fragments are released into the 
cytosol (reviewed in (Lee and Goldberg, 1998)) (Figure 9b).  
1.9.4 Inhibitors of Protein Degradation  
One possibility to study degradation of a specific protein is to selectively block one of the two 
discussed degradative pathways and to assess the effect on turnover of the protein of interest. 
NH4Cl, leupeptin and chloroquine can be used to inhibit lysosomal protein degradation (see e.g. 
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(Tanaka et al., 1986)). For analysis of proteasomal degradation several types of low­molecular­weight 
inhibitors are available. They can enter living cells and inhibit proteolysis specifically and reversibly 
without affecting other proteasomal functions. One such inhibitor is the peptide aldehyde Cbz­leu­
leu­leucinal (also called Z­leu­leu­leu­al or MG132), which primarily targets chymotrypsin­like 
proteolytic activity (Lee and Goldberg, 1996; Rock et al., 1994). However, peptide aldehydes have 
also been reported to inhibit individual lysosomal proteases and calpains. Thus observed effects of 
these proteasomal inhibitors must be confirmed by use of distinct inhibitors of proteasomal activity, 
which do not affect other degradative pathways (Rock et al., 1994). Of course, the same is true for 
the use of lysosomal inhibitors.  
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Figure 9| a| The 26S Proteasome Illustration from (Adams, 2004) The 20S Proteasome comprises two central ß rings 
flanked by two α­rings. Together with two 19S regulatory complexes and ATP it forms the 26S proteasomal complex.  | b| 
Protein Degradation Endosomal­lysosomal degradation (left side, adapted from (Luzio et al., 2007)) and proteasomal 
degradation (right side, adapted from (Lee and Goldberg, 1998)). 
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2 Aim of the Project  
The aim of this diploma thesis was to further characterize the endocytosis of MuSK and the role of 
two posttranslational modifications, phosphorylation and ubiquitination, in this process.  
Of special interest were  
� The effect of activation and consequent phosphorylation of MuSK on the internalization and 
degradation of MuSK  
� The role of MuSK mono­ and polyubiquitination in MuSK internalization and degradation  
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3 Results and Discussion  
3.1 Activation of MuSK in a Heterologous Cell System  
This project aimed at the establishment of a non­muscle cell system (heterologous cell system), in 
which MuSK can be stimulated artificially. Such a system would be useful for the investigation of 
MuSK endocytosis and internalization and associated processes. 
Muscle­specific kinase is expressed in myotubes but not in non­muscle cell lines like COS­7, HeLa, 
Phoenix or HEK293T cells. To study MuSK in such heterologous cells, it was introduced via transient 
or stable transfection. Two methods of MuSK stimulation were subsequently tested. First of all, it 
was tried to artificially activate MuSK by antibody­mediated clustering (Section 3.1.1). Secondly, it 
was tested whether agrin could be used to stimulate heterologously expressed MuSK. Unfortunately, 
heterologous cells also miss the muscle intrinsic machinery required for agrin­induced MuSK 
activation, which comprises, among other proteins, the transmembrane agrin receptor LRP4 and the 
cytoplasmic protein Dok7. It was investigated whether agrin­responsiveness could be reconstituted 
by co­transfection of cells with MuSK and LRP4 or all three proteins (Section 3.1.2).  
Both approaches would have yielded inducible experimental systems. They would have allowed 
activation of MuSK at a certain time point and analysis of the ensuing signaling processes. This would 
have been most convenient for tackling MuSK endocytosis. But in the establishment of these systems 
decisive obstacles were met. Thus, constitutively active and inactive MuSK mutants were used to 
investigate the effects of phosphorylation on MuSK internalization (Section 3.1.3.1). The mutants 
were transfected into the desired heterologous cells and differences in the transport processes in 
question were assessed. The required MuSK variants had already been created and simply had to be 
adapted according to experimental requirements.  
3.1.1 Antibody­Induced Activation of MuSK  
Heterologous cells were transiently transfected with N­terminally tagged MuSK (HA­MuSK, Myc­
MuSK) and incubated for 24 h to allow protein expression. To activate MuSK, antibodies specific for 
the protein tag (Myc, HA) were added to the cell culture medium. Binding of antibody to the N­
terminal tag of MuSK molecules should lead to clustering of RTKs and thereby induce trans­
autophosphorylation and activation as shown previously (Herbst and Burden, 2000; Hopf and Hoch, 
1998; Xie et al., 1997). Figure 10 depicts the principle of this approach using the example of Myc­
MuSK. MuSK­transfected cells not treated with antibodies were used as reference for activation. To 
assess the extent of antibody­induced activation, stimulated cells and control cells were lysed and 
MuSK was immunoprecipitated from the lysates. The precipitates were resolved via SDS­PAGE and 
the immunoblots were probed for phosphotyrosine (pTyr) and Myc. The signal intensities were 
quantified and the ratio of corresponding pTyr and Myc signals was calculated. This ratio mirrored 
the phosphorylation level of MuSK in a sample i.e. the portion of total MuSK that was 
phosphorylated as a result of antibody­treatment.  
19 
  
Figure 10| Antibody­mediated stimulation of N­terminally tagged MuSK Myc­MuSK comprises a Myc­tag (Myc) near the 
N­terminus. Upon heterologous expression of Myc­MuSK in non­muscle cells and integration of the protein into the plasma 
membrane (PM) this Myc­tag is exposed to the extracellular environment. Antibody specific for Myc that is added to the 
growth medium of Myc­MuSK expressing cells should interact with the Myc­tag and thereby cluster MuSK. MuSK 
aggregation should facilitate interaction of MuSK tyrosine kinase domains (TK) to induce MuSK trans­autophosphorylation.  
The method was tested once with HA­MuSK and in several independent experiments with Myc­MuSK 
in HEK293T cells. Unfortunately, both MuSK­variants are strongly overexpressed upon transient 
transfection. This apparently leads to aggregation of the protein in the plasma membrane and 
pronounced antibody­independent activation. Of course, basal, agrin­independent auto­activation of 
MuSK also occurs in muscle­cells but generally at lower levels. In order to stimulate MuSK activation, 
cells were incubated with antibodies at a concentration of 50 nM as described in Section 5.5.8. For 
Myc­MuSK stimulation in HEK293T cells, also the twofold concentration of 100 nM was tested. 
However, it was observed that antibody treatment failed to significantly increase MuSK 
phosphorylation in HEK293T cells (data not shown). As HEK293T cells are known to express 
heterologous proteins at especially high levels, it was decided to test the experimental setting in a 
different cell system exhibiting less expression of transiently transfected proteins and thus probably 
also less basal MuSK phosphorylation. Figure 11 depicts the results of two independent experiments 
in COS­7 cells. In the first experiment antibody­treated cells yielded slightly increased MuSK 
phosphorylation compared to two untreated controls. In contrast, phosphorylation after anti­ Myc­
incubation was even less than in the controls in the second experiment. Morever, phosphorylation 
levels in the two control samples strongly varied in both experiments.  
As demonstrated, antibody treatment failed to significantly increase MuSK phosphorylation. Possibly, 
binding of antibody successfully induced MuSK clustering and activation but this antibody­mediated 
activation was not strong enough to be discriminated from basal activation via biochemical methods, 
as suggested above. But Myc­antibodies might also have been unable sufficiently cluster Myc­MuSK 
to facilitate trans­autophosphorylation. Anti­Myc binds Myc­MuSK as it has been demonstrated to 
label Myc­MuSK by immunocytochemistry (data not shown) and was used for immunoprecipitation. 
Nonetheless, it was found that this experimental setting is inapt for studying heterologous MuSK 
activation and endocytosis in HEK293T and COS­7 cells.  
Myc 
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Figure 11| Quantification of Antibody­Mediated Stimulation of MuSK in COS­7 Cells COS­7 cells were transfected with 
Myc­MuSK and treated with 50 nM anti­Myc for 30 min or left untreated. The cells were lysed, Myc­MuSK was 
immunoprecipitated from the lysates with anti­Myc and resolved via SDS­PAGE. TF… transfection, Stim… stimulation, IP… 
immunoprecipitation, IB… immunoblot (antibody used for detection).| a| Immunoblots were probed for pTyr, stripped and 
probed for Myc (immunoblot of experiment 1).| b, c| The ratio of pTyr­ and Myc­signals was quantified for each sample. 
Ratios are depicted in % of pTyr/Myc­ratio of stimulated sample.  
3.1.2 Co­Expression of MuSK with Associated Muscle­Specific Proteins and 
Stimulation with Agrin  
In this approach it was assessed whether MuSK, if co­expressed with LRP4 can be activated with agrin 
in heterologous cells.  
To determine the efficiency of co­expression and the interaction between the expressed proteins, co­
transfected HEK293T cells were lysed. MuSK or LRP4 were immunoprecipitated from the lysates and 
analyzed via immunoblotting Figure 12a. MuSK precipitates were probed for LRP4 showed a specific 
a 
b 
c 
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band above 170 kDa. The band corresponded in size with the LRP4­signal detected in the lysates of 
co­transfected cells and in the lysates of cells transfected with LRP4 alone. In accordance, a specific 
MuSK signal was found when LRP4 was co­expression with MuSK and immunoprecipitated. Thus, it 
could be shown that MuSK and LRP4 were successfully co­expressed in HEK293T cells and interact 
with each other.  
For agrin­stimulation experiments, cells were co­transfected with MuSK­HA and LRP4­Myc and 
treated with agrin or left untreated. The cells were lysed, MuSK was precipitated from the lysates 
and the phosphorylation levels were determined via immunoblotting as described in Section 5.6.7.  
Again, it was found that MuSK strongly autophosphorylated upon heterologous expression as shown 
in Figure 12b and c. Moreover, no specific increase in MuSK phosphorylation was detected in MuSK 
precipitates derived from agrin­treated cells. Apparently, co­expression with LRP4 is not sufficient to 
render MuSK sensitive to agrin upon expression in HEK293T cells. The strong autophosphorylation 
might be the cause. But it has also been hypothesized that for stimulation of MuSK with agrin Dok7 
was required in addition to LRP4. To avoid transient transfection of three different plasmids, Dok7 
was stably transfected into HeLa and COS­7 cells. Both cell lines do not express heterologous proteins 
as highly as HEK293T cells after transient transfection. Hence, MuSK should autophosphorylate less 
in these cells. Dok7­positive HeLa and COS­7 cells should subsequently be transiently co­transfected 
with MuSK and LRP4 and used for agrin­induction experiments.  
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Figure 12| Co­Expression of MuSK and LRP4 in HEK293T Cells and Stimulation with Agrin| a| HEK293T cells were 
transfected with MuSK­HA, LRP4­Myc or both. Cells were lysed and aliquots of the lysates were taken. The rest of the 
lysates was subject to IP with antibodies specific for HA (anti­HA) or Myc (anti­Myc). The lysate aliquots and the precipitates 
were resolved via SDS­PAGE. The immunoblots were cut and the parts were probed for HA and Myc.| b| HEK293T cells 
were transfected with MuSK­HA, LRP4­Myc or both. Co­transfected cells were treated with agrin for 30min or left untreated 
and lysed. MuSK was precipitated from the lysates and the precipitates were resolved via SDS­PAGE. The immunoblots 
were probed for pTyr, stripped and probed for HA to detect MuSK.| c| MuSK phosphorylation in lysates of agrin stimulated 
and unstimulated cells co­transfected with MuSK and LRP4 was quantified (see 5.6.7) in three independent experiments.  
3.1.2.1 Generation of Single Cell Clones Stably Expressing Dok7 
HeLa and COS­7 cells were stably infected with retrovirus carrying C­terminally HA­tagged Dok7 
controlled by a c­Fos or a TK promoter (c­Fos Dok7­HA or TK Dok7­HA) (Kim et al., 2008). The TK 
promoter is a stronger promoter than the c­Fos promoter. Thus, the TK promoter should lead to 
higher Dok7 expression whereas the c­Fos promoter should cause more physiological Dok7 
expression levels. Dok7­positive cells were selected through cultivation in growth medium containing 
puromycin. Single­cell clones were picked and cultured and the expression level of Dok7 in the clones 
was determined. Dok7 expression was significantly higher in COS­7 clones than in HeLa clones. Two 
TK­Dok7­HA positive HeLa and two TK­Dok7­HA positive COS­7 clones exhibiting the highest and 
lowest Dok7­expression were used for further experiments (see Figure 13). This should allow 
controlling for artefacts resulting from different Dok7 expression levels.  
a 
b c 
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Figure 13| Quantification of Dok7 Expression in HeLa and COS­7 Clones Stably Infected with Dok7| a  Dok7 positive HeLa 
and COS­7 clones were lysed. Lysates were resolved by SDS­PAGE and immunoblots were probed for HA, to detect HA­
tagged Dok7, and actin.| b| HA and actin signals were quantified and the ratio of the two signals (HA/actin) was calculated 
for each clone. Black arrows mark the clones that were selected for further experiments.  
The selected clones were transfected with Myc­MuSK and FLAG­tagged LRP4 in several independent 
experiments. However, co­expression of the two proteins could never be detected biochemically. 
Moreover, the cells had undergone morphological changes due to repetitive passaging and long 
cultivation. COS­7 cells were no longer round­shaped but exhibited filopodia­like processes. HeLa 
cells were either rounder than usual or thinner and elongated. It was found that the selected, Dok7­
positive HeLa and Dok7 clones could only poorly be transiently transfected with further proteins or 
were completely resistant to additional transfection. Thus, the cells were unsuitable. 
3.1.3 Constitutive Activation & Inactivation of MuSK  
The establishment of an inducible model system for MuSK endocytosis was found to be more difficult 
than expected. Therefore, kinase­inactive and kinase­active MuSK mutants MuSK­K608A and MuSK­
LS745/746MT were used to study the role of phosphorylation in MuSK­endocytosis. In MuSK­K608A, 
arginine is expressed instead of a key lysine in the ATP binding site of MuSK, which abolishes the 
kinase activity of MuSK (Glass et al., 1997). MuSK­LS745/746MT comprises mutations that destabilize 
the conformation of the MuSK A loop. In the unphosphorylated form of MuSK, this loop sterically 
blocks the nucleotide and substrate binding sites. To create MuSK­LS745/746, Leu­745 and the first 
residue in the A loop Ser­746, which are involved in strong non­covalent interactions, were replaced 
by the corresponding amino acids of the insulin receptor kinase (IRK) (Till et al., 2002). The mutated 
amino acids do not fulfil the same functions thus weakening the inactive conformation of the A loop 
and rendering MuSK constitutively active. The MuSK mutants MuSK­K608A and MuSK–LS745/746MT 
were kindly provided by S.J. Burden. The mutants were modified by insertion of streptavidin­binding 
b 
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protein (SBP)­tags near the N­terminus of MuSK (see Section 5.6.9.4 and Figure 14). SBP strongly 
associates with streptavidin and allows tracking the tagged proteins with fluorophore­coupled 
streptavidin in internalization experiments. 
 
Figure 14| Wild­type SBP­MuSK and SBP­MuSK Mutants In SBP­MuSK­K608A lysine 608 (K608) was replaced by an arginine 
residue rendering the protein kinase inactive. SBP­MuSK­LS745/746MT contains methionine (M) and threonine (T) instead 
of leucine (L) and serine (S) residues at positions 745 and 746 and thus is constitutively phosphorylated if expressed in cells.  
3.1.3.1 Characterization of SBP­MuSK­K608A and SBP­MuSK­LS745/746MT in 
COS­7 Cells  
To characterize expression and phosphorylation levels of the modified phosphorylation mutants SBP­
MuSK­K608A and SBP­MuSK­LS745/746MT in comparison to wild­type SBP­MuSK, the three 
constructs were transiently transfected into COS­7 cells. Transfected cells were examined 
biochemically and via immunocytochemical stainings (Figure 15). In immunoblots, wild­type SBP­
MuSK showed weak phosphorylation most probably resulting from spontaneous clustering and auto­
phosphorylation. Such basal phosphorylation is, as explained previously, generally observed for 
MuSK wild­type variants expressed at high levels. However, phosphorylation of SBP­MuSK­
LS745/746MT was significantly stronger whereas SBP­MuSK­K608A was not phosphorylated. In 
immunocytochemical stainings pronounced tyrosine phosphorylation was detected in the areas of 
the cells where SBP­MuSK­LS745/746MT was localized. In contrast, SBP­MuSK­K608A positive cells 
stained only weakly for pTyr and no colocalization of MuSK­ and pTyr­staining was observed. Thus 
biochemical and immunocytochemical characterization confirmed that SBP­MuSK­K608A is kinase­
inactive whereas SBP­MuSK­LS745/746MT is strongly auto­phosphorylated in a constitutive, agrin­
independent manner.  
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Figure 15| Phosphorylation of SBP­MuSK wt, ­K608A & ­LS745/746MT| a| COS­7 cells transfected with SBP­MuSK wt, ­
K608A or –LS745/746MT were lysed. SBP­tagged MuSK variants were pulled down with streptavidin­coupled agarose beads 
(=streptavidin­PD… streptavidin­pull­down). PD­samples were resolved via SDS­PAGE and immunoblots were probed for 
pTyr, stripped and reprobed for MuSK.| b| SBP­MuSK variants K608A and LS745/746MT were transfected into COS­7 cells 
and the cells were immunocytochemically stained for pTyr (green) and MuSK (red). Scale bars, 25 µm. 
3.1.3.2 Internalization of SBP­MuSK­K608A and SBP­MuSK­LS745/746MT in 
COS­7 Cells  
Next it was examined whether phosphorylation of MuSK influences its endocytosis and consecutive 
intracellular targeting. For this purpose SBP­tagged wild­type MuSK (SBP­MuSK) and the two 
phosphorylation mutants SBP­MuSK­K608A and –LS745/746MT were expressed in COS­7 cells. Living 
cells expressing one of the three variants were shifted to 4°C to inhibit endocytosis and incubated 
with fluorophore­coupled streptavidin to label MuSK on the cell surface. Unbound streptavidin was 
removed and endocytosis was permitted by incubating the cells at 37°C. After different incubation 
times, the internalization process was stopped by cooling. The cells were washed, fixed and 
mounted.  
As demonstrated in Figure 16 wild­type MuSK was primarily localized at the cell membrane 
endocytosis was allowed. After 30min of incubation at 37°C SBP­MuSK was rather found in big 
vesicular structures near the cell nucleus and was even more concentrated in the perinuclear region 
after 60min. This change in localization suggests rapid internalization of the protein within 1h. A 
comparable redistribution process was observed for the two phosphorylation mutants K608A and 
LS745/746MT. No differences in the timecourse of internalization were observed. The structures to 
where the three MuSK variants were targeted were similar in morphology. These results suggest that 
the activation level of MuSK does not affect the internalization and degradation of MuSK in COS­7 
cells. However, it is possible that muscle cells might express specific proteins, which change MuSK 
targeting in response to its activation.  
a b 
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Figure 16| Internalization of wild­type SBP­MuSK, SBP­MuSK­K608A and SBP­MuSK­LS745/746MT in COS­7 Cells COS­7 
cells expressing wild­type SBP­MuSK, SBP­MuSK­K608A or SBP­MuSK­LS745/746MT were labeled with fluorophore­coupled 
streptavidin at 4°C. After removal of unbound streptavidin, the cells were directly fixed (0 min) or incubated for 30min or 
60min at 37°C before fixation. Scale bars, 10 µm. 
3.2 The Role of MuSK Ubiquitination in MuSK Endocytosis and Degradation  
Like MuSK, EGFR is a receptor tyrosine kinase that has been shown to be ubiquitinated in a ligand­
dependent manner (Haglund et al., 2003; Huang et al., 2006; Lu et al., 2007b). Haglund et al. 
analyzed the role of mono­ and polyubiquitination in EGFR endocytosis and for this purpose created 
EGFR­Ub chimeras (Haglund et al., 2003). In these chimeras, the intracellular domain of the RTK was 
replaced by either wild­type ubiquitin (EGFR­Ub) or a mutated form of ubiquitin (EGFR­Ub­mut). In 
this mutated variant, K48 of Ub had been replaced by an arginine residue and the last two glycines 
had been deleted. As K48 and the C­terminal glycines of Ub are commonly involved in 
polyubiquitination the mutated chimera was not polyubiquitinated. Missing the intracellular portion 
of EGFR, EGFR­Ub and –Ub­mut were completely devoid of cytosolic signaling domains. Hence, 
differential ubiquitination but not additional signaling processes could influence endocytosis of these 
proteins.  
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Expression vectors encoding the two ubiquitin variants were kindly provided by S. Sigismund and P.P. 
Di Fiore and were used by R. Herbst to create MuSK­Ub chimeras (unpublished data). These chimeras 
were modified by addition of an N­terminal HA­tag (see Section 5.6.9.5 and Figure 17).  
 
Figure 17| Wild­type HA­MuSK and HA­MuSK­Ub chimeras HA­MuSK­Ubwt & HA­MuSK­Ubmut Wild­type MuSK N­
terminally fused to an HA (HA­MuSK) was used as control in internalization experiments. HA­MuSK­Ubwt is structurally 
similar to HA­MuSK but the intracellular portion of MuSK was replaced by a FLAG­protein tag and wild­type ubiquitin. In 
contrast to HA­MuSK­Ubwt, HA­MuSK­Ubmut contains two mutations in the Ub portion. Lysine 48 (K48) of Ub was replaced 
by arginine (R) and the last two glycines of the Ub portion were deleted.  
3.2.1 Characterization of HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 
Cells  
HA­MuSK­Ubwt and HA­MuSK­Ubmut were expressed in COS­7 cells and characterized biochemically 
and by immunocytochemistry.  
Lysates of COS­7 cells transfected with HA­MuSK­Ubwt or HA­MuSK­Ubmut were analyzed via 
immunoblotting as depicted in Figure 18a. In the case of HA­MuSK­Ubwt, probing with anti­HA 
yielded a weak band of 85 ­ 90 kDa and a high molecular weight smear of more than 170 kDa. This 
kind of blurred pattern is characteristic for polyubiquitinated proteins (see e.g. (Haglund et al., 
2003)). Upon polyubiquitination, protein molecules of one type are generally modified with 
polyubiquitin chains of varying lengths. Consequently individual protein molecules migrate 
differently during SDS­PAGE and produce a protein ladder or smear rather than a single band. The 
weak single band and the smeary pattern were also detected in immunoprecipitates of HA­MuSK­
Ubwt. In contrast, HA­MuSK­Ubmut gave two bands of less than 100 kDa. The smaller band was of 
the same size as the single band detected for HA­MuSK­Ubwt whereas the other band migrated 10­
15kDa higher. Intriguingly, this size shift correlates with the addition of one Ub molecule (Shih et al., 
2003). HA­MuSK­Ubmut also appeared as high molecular weight smear in lysates and after 
immunoprecipitation. But relative to the signal intensity of the smaller, ~85 kDa band the high­
molecular pattern was less pronounced than in HA­MuSK­Ubwt lysates and immunoprecipitates.  
Thus, biochemical analyses indicate that HA­MuSK­Ubwt is expressed primarily as polyubiquitinated 
protein. However, it also occurs in the unmodified form, which is bona fide monoubiquitinated as it 
comprises full length Ub. HA­MuSK­Ubmut occurs in two species of approximately 85 and 95 kDa. It is 
suggested that the 85 kDa species represents the unmodified, bona fide monoubiquitinated protein 
The 95 kDa species most probably carries an additional Ub molecule and thus is di­ubiquitinated. 
Nonetheless also polyubiquitinated HA­MuSK­Ubmut was detected. Apparently the K48R mutation in 
the Ub portion and the deletion of the two C­terminal glycines of does not completely inhibit 
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polyubiquitination. But as explained in Section 1.7 other lysine residues of Ub such as K63 can serve 
as acceptor sites for Ub chains.  
To confirm that both chimeras actually comprise Ub and that the 95 kDa species of HA­MuSK­Ubmut 
further modified with a single ubiquitin molecule the experiment depicted in Figure 18a was 
repeated and immunoblots were probed with P4D1. P4D1 is a monoclonal antibody specific for 
mono­ and polyubiquitin commonly used for ubiquitin detection. It was applied by Haglund et al. to 
detect the EGFR­Ub chimeras and thus was expected to bind HA­MuSK­Ubwt and –Ubmut (Haglund 
et al., 2003). Surprisingly, the antibody failed to bind the 85 kDa species of either of the two chimeras 
and the 95 kDa species of HA­MuSK­Ubmut. It exclusively detected the polyubiquitin smears (data 
not shown). It can only be hypothesized that P4D1 binding to the small chimera species was too 
weak to yield a specific signal. This would also be in accordance with the results shown in Figure 19.  
Expression of the two MuSK­Ub chimeras was also analysed by immunocytochemistry as 
demonstrated in Figure 18b. For the stainings COS­7 cells transfected with HA­MuSK­Ubwt or HA­
MuSK­Ubmut were fixed and the plasma membrane was permeabilized with detergent or left intact. 
Antibodies cannot diffuse through intact plasma membrane. Hence, only MuSK expressed on the cell 
surface was stained in the case of unpermeabilized cells. For both chimeras an evenly distributed, 
dotted surface staining was observed, but the spots appeared to be smaller on cells expressing HA­
MuSK­Ubwt. Intracellularly, HA­MuSK­Ubwt was detected throughout the cell but primarily near the 
nucleus. In HA­MuSK­Ubmut expressing cells the staining was much stronger and more pronounced 
in the peripheral areas of the cells. Apparently, HA­MuSK­Ubmut is expressed far better than HA­
MuSK­Ubwt. The preferred localization of HA­MuSK­Ubwt near the cell nucleus suggests that it might 
be degraded to some extent right after synthesis. Nonetheless, it could be demonstrated by surface 
stainings that both chimeras are expressed as functional proteins that are integrated into the plasma 
membrane.  
29 
 
Figure 18| Expression of HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 cells| a| For biochemical analysis COS­7 cells 
transfected with HA­MuSK­Ubwt, HA­MuSK­Ubmut and untransfected cells were lysed and subjected to 
immunoprecipitation with antibodies against HA (anti­HA). Lysate aliquots and immunoprecipitates were resolved via SDS­
PAGE and immunoblots were probed for HA.| b| For immunocytochemical stainings COS­7 were transfected with HA­
MuSK­Ubwt or HA­MuSK­Ubmut. Cells were permeabilized and stained for HA to detect intracellular and surface MuSK. To 
exclusively detect surface MuSK, transfected cells were not permeabilized previous to staining. Scale bars, 25 µm.  
Figure 19 depicts an internalization experiment performed with the MuSK­Ub­chimeras, in which 
endocytosis and ubiquitination of HA­MuSK­Ubwt and HA­MuSK­Ubmut was studied. Internalization 
of the chimeras was tracked as illustrated in Figure 19a. Living COS­7 cells transfected with HA­MuSK­
Ubwt or HA­MuSK­Ubmut were incubated with anti­HA antibodies at 4°C. Thereby, MuSK expressed 
on the cell surface was labeled while at the same time endocytosis was blocked. Unbound antibody 
was removed and the cells were put to 37°C, which permitted internalization, and incubated for 5 to 
120min. Internalization was stopped by cooling the cells to 4°C. By incubating the intact cells in 
buffer of low pH, antibodies were stripped from MuSK molecules that had not been internalized until 
then. Subsequently, the cells were fixed, permeabilized and anti­HA bound to internalized MuSK was 
detected with fluorophore­coupled secondary antibodies. Ubiquitination was detected subsequently 
by conventional immunocytochemical staining using P4D1 antibody.  
Figure 19b shows that internalization of HA­MuSK­Ubwt and HA­MuSK­Ubmut could be visualized by 
the described assay. But ubiquitination of the two chimeras was not clearly demonstrated. As 
mentioned above P4D1 antibody should bind mono­ and polyubiquitin but failed to detect the bona 
fide monoubiquitinated species of HA­MuSK­Ubwt and HA­MuSK­Ubmut in immunoblotting. In 
immunocytochemical stainings, P4D1 was found to stain HA­MuSK­Ubwt positive cells in areas where 
HA­MuSK­Ubwt was concentrated. However, HA­MuSK­Ubmut positive cells exhibited no specific 
P4D1 staining. Apparently P4D1 failed to bind the Ubmut­chimera. As mentioned above, another 
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explaination might be that P4D1 stains monoubiquitin only weakly and thus only yields detectable 
signal upon overexpression of polyubiquitinated protein. Considering that all cells contain 
ubiquitinated proteins but were not stained with P4D1 supports this hypothesis.  
 
Figure 19| Internalization of HA­MuSK­Ub chimeras and Detection of Ub| a| The scheme illustrates how internalization of 
HA­tagged MuSK molecules was tracked.| b| Untransfected COS­7 cells and cells expressing HA­MuSK­Ubwt and HA­MuSK­
Ubmut were incubated with anti­HA at 4°C. Internalization was permitted by incubation at 37°C for 30min. Not internalized 
antibodies were removed from the surface by stripping. Cells were fixed and permeablized. Internalized anti­HA was 
detected with a corresponding fluorophore­coupled secondary antibody (green). Ubiquitin was detected with antibodies 
specific for Ub (red). The rightmost panels represent overlays of the two stainings. For details see text. Scale bars, 25 µM.   
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3.2.2 Stability of HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 cells  
The stability of wild­type HA­MuSK and the two HA­MuSK­Ub chimeras was assessed by the use of 
cycloheximide, a potent inhibitor of protein synthesis. The prevailing pool of proteins in the cells is 
degraded while no new protein is formed. Consequently, the total amount of each type of protein in 
a cell gradually decreases according to the half­life of the protein, which can be visualized by 
immunoblotting.  
To determine the half­life of HA­MuSK, COS­7 cells expressing HA­MuSK were treated with 
cycloheximide for 5 to 120min, lysed and resolved via SDS­PAGE. The amount of intact HA­MuSK in 
each sample was quantified and compared to the amount of protein in untreated cells expressing 
HA­MuSK. The stability of the two MuSK­Ub chimeras was determined accordingly (Figure 20 and 
Figure 21). In the analyses EGFP was used as internal standard. It served as transfection control and 
as reference for quantification. COS­7 cells were always co­transfected with EGFP and the HA­MuSK 
variants. EGFP is highly stable with a half­life of more than 24h (Barrow et al., 2005). Thus, the total 
amount of EGFP should not decrease significantly after two hours of translational inhibition. 
Quantification of protein levels of the three HA­MuSK variants relative to EGFP therefore excluded 
errors resulting from inconsistent transfection efficiency and pipetting errors.  
As demonstrated in Figure 20a HA­MuSK was detected as single specific band in immunoblots. In 
contrast, HA­MuSK­Ubwt and HA­MuSK­Ubmut occurred in distinct species, which had to be 
quantified individually. For the 85 kDa and the 95 kDa species of HA­MuSK­Ubmut and the weak HA­
MuSK­Ubmut smear half­lives of about 70min, 90 ­ 100 min and 110 ­ 120 min were determined. 
Thus the85 kDa and the 95 kDa species exhibited slightly higher stability than the wild­type form of 
HA­MuSK with a half­life of about 60 min whereas HA­MuSK­Ubmut smear was about twice as stable. 
The 85 kDa species of HA­MuSK­Ubwt was significantly less stable and had a half­life of about 15 ­
 20 min. In contrast, the amount of HA­MuSK­Ubwt polyubiquitin smear remained constant even 
after 60min of translational inhibition and only slightly decreased to around 60 % after 2 h. This 
might suggest that the bona fide monoubiquitinated 85 kDa species of HA­MuSK­Ubwt is degraded 
far more quickly than the polyubiquitin variant or wild­type MuSK. However, both forms of HA­
MuSK­Ubwt occur in one cell and prevalence of the two might be coupled to a chemical equilibrium, 
which might favor the polyubiquitinated state. Therefore, reduction of the 85 kDa species might not 
result from degradation but from ubiquitination of this form. It is suggested that the 85 kDa species 
of HA­MuSK is quickly ubiquitinated after protein synthesis. This might have also affected the 
determination of the half­life of polyubiquitinated HA­MuSK­Ubwt. Upon inhibition of protein 
synthesis, the 85 kDa species was probably ubiquitinated and moved to the pool polyubquitinated 
protein during short incubation with cycloheximide. When most of the 85 kDa species was 
polyubiquitinated the degradation of polyubiquitinated HA­MuSK­Ubwt became apparent. This may 
have increased the apparent half­life of polyubiquitinated HA­MuSK­Ubwt in the analysis. Thus, the 
half­lives of HA­MuSK and the different species of the MuSK­Ub chimeras that were determined by 
cycloheximide experiments were verified by internalization experiments as reported in Section 3.2.3.  
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Figure 20| Stability of HA­MuSK, HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 Cells| a­c| COS­7 cells expressing one of 
the three MuSK variants were treated with cycloheximide for 5, 15, 30, 60, 120 min or left untreated. The cells were lysed 
and the lysates were resolved via SDS­PAGE. Immunoblots were cut and the parts were probed for HA and GFP. Lysates of 
untransfected COS­7 cells (UT) resolved and blotted in parallel were used to identify unspecific bands (marked by an 
asterisk).  
b a 
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Figure 21| Stability of HA­MuSK, HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 Cells HA and GFP signals were detected in 
immunoblots as depicted in Figure 20 and were quantified. HA/ GFP­ratios were calculated for each time point (HA­MuSK: 
n=3, HA­MuSK­Ubwt and HA­MuSK­Ubmut: n=4). The results of timepoints 5, 15, 30, 60 and 120 min of a timecourse were 
plotted in percent relative to the corresponding HA/ GFP­ratio at timepoint 0 min. The dashed lines indicate the 
approximate half­lives of HA­MuSK and the distinct species of HA­MuSK­Ubwt and HA­MuSK­Ubmut.  
3.2.3 Internalization of HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 Cells  
Ubiquitination has been described to influence internalization and intracellular targeting of proteins. 
Therefore, endocytosis and transport of HA­MuSK­Ubwt and HA­MuSK­Ubmut was further 
investigated via the internalization assay described in Section 3.2.1 and depicted in Figure 19a. Figure 
22b illustrates internalization of HA­MuSK­Ubwt and HA­MuSK­Ubmut after 15 min and 60 min. After 
15 min specific intracellular staining was observed for both chimeras. When cells expressing on of the 
MuSK­Ub­chimeras were fixed directly after antibody­incubation without allowing internalization 
(time point 0 min) only faint unspecific staining or no staining was visible. This demonstrates that 
antibodies bound to surface MuSK were efficiently removed by stripping. After 60 min both chimeras 
were found concentrated near the cell nucleus in vesicular structures. The experiment was repeated 
several times but significant difference in the speed of endocytosis or intracellular transport to the 
nucleus was not observed. This observation not consistent with the results described in Section 3.2.2 
and suggests that both chimeras are comparably stable. However, it cannot be excluded that only 
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polyubiquitinated HA­MuSK­Ubwt was transported to the cell surface and was therefore visualized in 
the stainings. The 85 kDa species could have been degraded before being integrated into the plasma 
membrane or transformed into polyubiquitinated HA­MuSK­Ubwt. Unfortunately, it was not possible 
to discriminate the different species of HA­MuSK­Ubwt and HA­MuSK­Ubmut in this assay.  
 
Figure 22| Internalization of HA­MuSK­Ubwt and HA­MuSK­Ubmut in COS­7 Cells COS­7 expressing HA­MuSK­Ubwt and 
HA­MuSK­Ubmut were incubated with anti­HA at 4°C. Then the cells were either directly stripped (0min) or MuSK 
internalization was permitted by incubation at 37°C for 15 min and 60 min. Scale bars, 25 µm.  
3.2.4 Colocalization of HA­MuSK­Ubwt and HA­MuSK­Ubmut with Rab7 
during Internalization  
As the speed of internalization of HA­MuSK­Ubwt and HA­MuSK­Ubmut was comparable it was 
checked whether differential ubiquitination influenced which degradation pathway MuSK was 
targeted. For this purpose, HA­MuSK, HA­MuSK­Ubwt and HA­MuSK­Ubmut were co­transfected with 
Rab7, which is a marker of late endosomal vesicles. The same internalization experiment as 
described above was performed and localization of the three MuSK variants relative to Rab7 was 
examined (Figure 23). Again, no specific difference was observed between HA­MuSK and the two 
MuSK­Ub chimeras. After 60 min of internalization all three proteins co­localized with Rab7 in 
vesicular structures near the cell nucleus. HA­MuSK­Ubwt was sometimes found in smaller vesicles 
than the other two variants. However, this may have resulted from the lower expression level of HA­
MuSK­Ubwt than from differences in internalization. Apparently, HA­MuSK, HA­MuSK­Ubwt and HA­
MuSK­Ubmut are targeted to the endosomal­lysosomal degradation pathway with similar efficiency. 
This hypothesis needs to be verified in further experiments. HA­MuSK­Ubwt and HA­MuSK­Ubmut 
expressing cells were treated with the lysosomal inhibitors chloroquine and leupeptin and the 
proteasomal inhibitor MG132. However, breakdown of the chimeras was not successfully blocked 
even with a combination of lysosomal and proteasomal inhibitors (data not shown). Control 
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experiments with proteins for which the degradation pathway has been determined were not 
performed. Thus it is not certain whether the inhibitors were applied correctly.  
 
Figure 23| Internalization of HA­MuSK, HA­MuSK­Ubwt and HA­MuSK­Ubmut and Co­localization with Rab7 Rab7­EGFP 
was co­expressed with HA­MuSK, HA­MuSK­Ubwt or HA­MuSK­Ubmut in COS­7 cells. Surface MuSK was labeled by 
incubating the cells with anti­HA at 4°C. Then the cells were either directly stripped (0 min) or MuSK internalization was 
permitted by incubation at 37°C for 60 min. Scale bars, 25 µm.  
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4 Conclusion and Outlook  
An inducible, heterologous model system for MuSK activation would be a useful tool for the 
investigation of MuSK internalization. But as reported, the establishment of such a system has been 
and might also in the future be hampered by several factors: First of all, heterologous expression of 
MuSK generally results in overexpression of the protein and strong basal autophosphorylation. It can 
be concluded from the performed experiments that transient transfection is for this reason inapt for 
the reconstitution of MuSK stimulation. Alternatively, MuSK and associated proteins could be stably 
expressed in non­muscle cells at a physiological expression level. However, the number of proteins 
that can be (stably) transfected into a cell is limited. Stable cell lines expressing e.g. MuSK, LRP4 and 
Dok7 as created by the group of S. Burden (Bergamin et al.) might allow studying the interplay of the 
three proteins. But it is unclear whether such cells are suitable for studying agrin­stimulated MuSK 
endocytosis. Possibly several additional muscle­specific proteins are needed for a functional MuSK 
internalization model system. In this case, the complexity of the agrin/ LRP4/MuSK­signaling cascade 
might exceed the possibilities of a heterologous cell system. But if MuSK, LRP4 and Dok7 combined 
with only a few other proteins were found to render MuSK responsive to agrin in non­muscle cells it 
would greatly enhance our understanding of the agrin signaling cascade.  
Lacking a working model system, the results described in this thesis were gained by transfection of 
non­muscle cells with mutant MuSK and associated proteins. Kinase­inactive and kinase­active MuSK 
variants were used to determine the effects of MuSK phosphorylation on its endocytosis. Zhu et al. 
reported that stimulation of MuSK with agrin induces rapid internalization of the kinase, which is 
required for AChR clustering. However, constitutively active and inactive MuSK mutants were found 
to exhibit no differences in the extent or speed of internalization upon heterologous expression in 
COS­7 cells. This implies that regulation of MuSK internalization is independent of its kinase activity. 
Increased endocytosis in response to agrin might be a consequence of MuSK clustering by LRP4. This 
process cannot be reconstituted in heterologous cells so far. Thus, it would have to be assessed in 
muscle cells whether internalization of kinase­inactive MuSK changes upon agrin stimulation. The 
experiments described in this thesis were performed in COS­7 cells and thus do not exclude the 
possibility that phosphorylation regulates MuSK internalization in muscle cells. Such a scenario would 
suggest the existence of a muscle­specific regulator of internalization that interacts with 
phosphorylated MuSK. MuSK mutants carrying point mutations at individual phosphorylation target 
sites might help identifying such downstream signaling.  
The second project discussed in this thesis concentrated on MuSK ubiquitination. As reported by Lu 
et al., MuSK expression on the muscle cell surface is regulated by ubiquitination in response to agrin­
stimulation (Lu et al., 2007b). To further characterize the influence of ubiquitination on MuSK 
targeting MuSK­Ub chimeras comprising wild­type (HA­MuSK­Ubwt) or mutant Ub (HA­MuSK­Ubmut) 
were used. Whereas the HA­MuSK­Ubwt was predominantly polyubiquitinated, HA­MuSK­Ubmut 
occurred to the biggest part in bona fide monoubiquitinated or di­ubiquitinated forms. As reported, 
experiments concentrated on the internalization of the two chimeras in comparison to wild­type 
MuSK in COS­7 cells. It was found that both chimeras were internalized and degraded in a similar way 
as wild­type MuSK in spite of the deletion of the cytoplasmic MuSK domain and the different 
ubiquitination levels. The findings could not be supported with inhibitor experiments due to 
methodical problems. However, there was no indication that posttranslational modification by 
ubiquitin determines by which pathway MuSK is degraded. It has been suggested that activation­
dependent ubiquitination of EGFR decreases clathrin­dependent EGFR endocytosis and thus EGFR 
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recycling and enhances clathrin­independent endocytosis and degradation of the receptor. The 
created MuSK­Ub chimeras provide a good tool to investigate whether recycling of MuSK is regulated 
accordingly. The internalization assay established in this thesis could be adapted for the purpose. 
However, it can be hypothesized that correct targeting of ubiquitinated MuSK (and of MuSK in 
general) is dependent on muscle­specific mechanisms. Regulation of MuSK breakdown in COS­7 did 
apparently not depend on the intracellular domain of MuSK, which was absent in MuSK­Ub chimeras. 
Therefore, HA­MuSK­Ubwt and HA­MuSK­Ubmut should be tested in muscle cells. This has not been 
done so far but might reveal differences in MuSK targeting that were not observed in heterologous 
cells.  
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5 Materials and Methods 
5.1 Materials  
Table 1| Cell Culture Dishes 
Cell Culture Dish Supplier 
10 cm IWAKI  
6 cm NUNC  
3.5 cm IWAKI  
6 well IWAKI  
12 well NUNC  
24 well IWAKI  
Cultube sterile culture tube with cap, polypropylene, 4 mL  Simport  
 
5.2 Plasmids  
Table 2| Non­Commercial Plasmids  
Plasmids Gene Vector Source Reference 
C­Ag 4.8 C­terminal half of agrin, 
N­terminus deleted 
pCMV C. Fuhrer (Ferns et al., 1993) 
CMV/ HA­MuSK N­terminally tagged 
MuSK 
unknown, Amp+, 
CMV­promoter 
R. Herbst unpublished data 
GFP­Rab7 wt Rab7 wt pEGFP­C1 C. Bucci  (Bucci et al., 2000) 
pBabe/ TK Dok7­HA C­terminally tagged 
Dok7 
pBabe, TK promoter S. Burden (Kim et al., 2008) 
pBabe/c­Fos Dok7­
HA 
C­terminally tagged 
Dok7 
pBabe, c­Fos 
promoter 
S. Burden (Kim et al., 2008) 
pBluescript/MuSK­
Ubmut 
MuSK­Ubmut (human 
Ub) 
pcDNA3 R. Herbst unpublished data 
pcDNA3/ 
HAMUbmut 
HA­MuSK­Ubiquitin­mut pcDNA3 M. Schlauf * 
pcDNA3/ HAMUbwt HA­MuSK­Ubiquitin­wt pcDNA3 M. Schlauf * 
pcDNA3/ MuSK­HA C­terminally tagged 
MuSK 
pcDNA3 D. Hantai (Chevessier et al., 
2004)  
pcDNA3/ SBP­MuSK  SBP(2x)­MuSK pcDNA3 R. Herbst unpublished data 
pcDNA3/SBP­MuSK­
K608A 
SBP(2x)­MuSK­K608A pcDNA3 M. Schlauf * 
pcDNA3/SBP­MuSK­
LS745/746MT 
SBP(2x)­MuSK­
LS745/746MT 
pcDNA3 M. Schlauf * 
pLitmus 29/MuSK­
Ubwt 
MuSK­Ubwt (sint Ub) pcDNA3 R. Herbst unpublished data 
RSV/ Myc­MuSK MuSK with Myc­tag near 
N­terminus 
unknown, Amp+, 
RSV­promoter 
R. Herbst (Herbst and Burden, 
2000) 
RSV/ SBP­MuSK­
K608A 
SBP(4x)­MuSK­K608A unknown, Amp+, 
RSV­promoter 
S. Luiskandl unpublished data 
RSV/ SBP­MuSK­
LS745/746MT 
SBP(4x)­MuSK­
LS745/746MT 
unknown, Amp+, 
RSV­promoter 
S. Luiskandl unpublished data 
* for details see Section 5.6.9  
Table 3| Commercial Plasmids  
Vector  Source  
pcDNA3 Invitrogen  
pEGFP­N2 Clontech  
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5.3 Chemicals and Reagents  
Table 4| DNA Purification and Extraction Kits 
Reagents Supplier 
GeneJETTM Plasmid Miniprep Kit Fermentas Life Sciences  
Pure LinkTM, HiPure Plasmid Midiprep Kit invitrogen 
GeneJETTM Gel Extraction Kit Fermentas Life Sciences  
 
Table 5| Antibodies ­ Immunocytochemistry  
Antibody Supplier 
Anti­HA antibody produced in rabbit Sigma­Aldrich Co., Sigma 
Anti­Rabbit IgG (of Donkey) Cy3 conjugated Affini Pure Jackson ImmunoResearch Laboratories, Inc.  
Anti­Rabbit IgG (of Donkey) DyLight488 Jackson ImmunoResearch Laboratories, Inc.  
DYKDDDK Tag Antibody (anti­FLAG) (Biotinylated) Cell Signaling Technology, Inc. 
DyLight488­conjugated Streptavidin Jackson ImmunoResearch Laboratories, Inc.  
DyLight649­conjugated Streptavidin Jackson ImmunoResearch Laboratories, Inc.  
Monoclonal ANTI­c­MYC clone 9E10 Sigma­Aldrich Co., Sigma 
Phosphotyrosin Mouse mAb (P­Tyr­100) Cell Signaling Technology, Inc. 
Ubiquitin (P4D1) Mouse mAb Cell Signaling Technology, Inc. 
 
Table 6| Antibodies – Immunoblotting  
Antibody Supplier 
Anti­Mouse IgG (of Goat), Peroxidase­conjugated  Jackson ImmunoResearch Laboratories, Inc.  
Anti­Rabbit IgG (of Goat), Peroxidase­conjugated  Jackson ImmunoResearch Laboratories, Inc.  
GFP (B­2) Santa Cruz Biotechnology, Inc. 
HA­Tag (6E2) Mouse mAb  Cell Signaling Technology, Inc. 
Monoclonal ANTI­c­MYC clone 9E10 Sigma­Aldrich Co., Sigma 
Monoclonal ANTI­FLAG M2, Clone M2 (ms) Sigma­Aldrich Co., Sigma 
MuSK­Antibody (RbαMuSK) polyclonal C. Fuhrer, Ph.D., Zürich 
Phosphotyrosin Mouse mAb (P­Tyr­100) * Cell Signaling Technology, Inc. 
p­Tyr (PY99) * Santa Cruz Biotechnology, Inc. 
Purified Mouse Anti­Actin Ab­5 BD Transduction Laboratories  
Ubiquitin (P4D1) Mouse mAb Cell Signaling Technology, Inc. 
* to detect pTyr in immunoblotting a mix of PY99 and P­Tyr­100 diluted in 5 % BSA/ TBS­T was used  
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Table 7| List of Chemicals and Reagents  
Reagent Supplier 
Acetic acid glacial (100%) Carl Roth GmbH + Co. KG 
Aprotinin Carl Roth GmbH + Co. KG 
BES Carl Roth GmbH + Co. KG 
Bromphenol Blue Carl Roth GmbH + Co. KG 
Chloroquine  AppliChem GmbH 
Cycloheximide Sigma‐Aldrich Co., Fluka Analytical  
DMEM with 4.5g/L‐Glucose  Lonza Group Ltd 
EGTA  Carl Roth GmbH + Co.  
FBS  PAA Laboratories GmbH 
Glycerol Carl Roth GmbH + Co.  
Glycine Carl Roth GmbH + Co. KG 
HEPES  Carl Roth GmbH + Co. KG 
Igepal CA 630 (NP‐40) Sigma‐Aldrich Co., Fluka Analytical  
KCl Carl Roth GmbH + Co. KG 
KH2PO4 Carl Roth GmbH + Co. KG 
Leupeptin Roche Diagnostics GmbH  
Milk powder  Carl Roth GmbH + Co. KG 
Mowiol 4‐88 Carl Roth GmbH + Co. KG 
Na2HPO4 Carl Roth GmbH + Co. KG 
Na2HPO4·2H2O Carl Roth GmbH + Co. KG 
NaCl Carl Roth GmbH + Co. KG 
Na‐Desoxycholat Sigma‐Aldrich Co., Fluka Analytical  
NaF Sigma‐Aldrich Co. 
NaOH Carl Roth GmbH + Co. KG 
OptDMEM I + GlutaMAX ‐I (1 x) Life Technologies, Invitrogen, GIBCO 
Page Ruler Prestained Protein 
Ladder #SM0671 
Fermentas GmbH 
Penicillin/ Streptomycin  PAA Laboratories GmbH 
Pepstatin A US biological  
PFA Sigma‐Aldrich Co., Fluka Analytical  
Phenylmethylsulfonylfluorid 
(PMSF) 
Carl Roth GmbH + Co. KG 
Protein A agarose beads  Roche Diagnostics GmbH  
Protein G agarose beads  Roche Diagnostics GmbH  
Puromycin  Sigma‐Aldrich Co. 
Restriction Enzymes Fermentas Life Sciences 
Rotiphorese Gel 40 (40% 
acrylamide)  Carl Roth GmbH + Co KG 
Shrimp Alkaline Phosphatase, 
1u/µL Fermentas GmbH 
Sodium dodecyl sulfate (SDS) SERVA Electrophoresis GmbH 
Sodium Orthovanadate Sigma‐Aldrich Co. 
ß‐mercaptoethanol Carl Roth GmbH + Co. KG 
Streptavidin Agarose Merck KGaA, Novagen 
T4 ligase, 1000u, 5u/µL Fermentas GmbH 
TEA Sigma‐Aldrich Co., Fluka Analytical  
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Reagent  Supplier  
Tris‐(hydroxymethyl)‐
aminomethan (Tris) 
Carl Roth GmbH + Co. KG 
Tris‐(hydroxymethyl)‐
aminomethanhydrochlorid (Tris‐
HCl) 
Carl Roth GmbH + Co. KG 
Triton X‐100 Carl Roth GmbH + Co. KG 
Trypsin‐EDTA  PAA Laboratories GmbH 
Turbofect in vitro Transfection 
Reagent  
Fermentas GmbH 
Tween 20 Carl Roth GmbH + Co. KG 
Z‐Leu‐Leu‐Leu‐al (MG132) Sigma‐Aldrich Co. 
 
5.4 Solutions and Buffers  
Table 8| 10 x PBS 
Reagent  Concentration 
NaCl 1.37 M 
KCl 27 M 
Na2HPO4·2 H2O  43 M 
KH2PO4  14 M 
To yield a 1 x PBS working solution the 10 x PBS stock solution was diluted 1:10. The working solution 
had a pH of about 7.3.  
Table 9| 4% PFA/ PBS  
Reagent  Amount Concentration 
PFA 0.8 g 4 % 
1 x PBS 20 mL   
0.5 M NaOH 50 µL  1.25 mM 
0.8 g PFA were dissolved in 20mL 1 x PBS and 50 µL 0.5 M NaOH were added. The solution was 
heated to 50‐100°C and stirred until the PFA had completely dissolved, then filtered with a folded 
filter (ROTH Art. CA16.1, Rotilabo ®‐Faltenfilter, qualitativ) and stored at 4°C. The solution had to be 
pH‐neutral, which was checked with pH‐indicator strips. 4 % PFA/PBS wasn’t used for longer than 
two weeks after preparation. 
Table 10| 4 x SDS Loading Buffer  
Reagent  Amount Concentration  
1 M Tris‐Cl, pH 6.8 2.4 mL 240 mM 
100 % ß‐mercaptoethanol 1 mL 8 %  
20 % SDS 2 mL 8 %  
100 % glycerol 4 mL  40 %  
ddH2O 0.6 mL  
bromphenol blue a few grains  
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Table 11| 50 x TAE 
Reagent  MW (g/mol) Amount  
Tris  121.14 g/mol 242 g  
Acetic Acid glacial (100 %)  57.1 mL 
0.5M EDTA (pH 8.0)   100 mL  
dH2O   adjusted to 1 L 
 
5.5 Cell Culture 
5.5.1 Cell Culture Conditions  
Table 12| HEK293T Growth Medium 
Reagent Concentration 
DMEM  
FBS 10 % 
Pen/Strep 1 x 
 
Table 13| Cell Types and Culture Conditions  
Cell Type  Culture Conditions  
HEK293T  HEK293T growth medium, 37°C, 5 % CO2  
COS‐7 HEK293T growth medium, 37°C, 5 % CO2  
HeLa  HEK293T growth medium, 37°C, 5 % CO2  
Phoenix  HEK293T growth medium, 37°C, 5 % CO2  
Phoenix A  HEK293T growth medium, 37°C, 5 % CO2  
COS‐7 TK Dok7‐HA  HEK293T growth medium + 1µg/mL puromycine, 37°C, 5 % CO2  
COS‐7 c‐Fos Dok7‐HA  HEK293T growth medium + 1µg/mL puromycine, 37°C, 5 % CO2  
HeLa TK Dok7‐HA  HEK293T growth medium + 0.5µg/mL puromycine, 37°C, 5 % CO2  
HeLa c‐Fos Dok7‐HA  HEK293T growth medium + 0.5µg/mL puromycine, 37°C, 5 % CO2  
 
5.5.2 Preparation of Agrin/ OptiMEM  
Agrin/ OptiMEM was not prepared for this diploma thesis but was already available. The following 
protocol has the purpose to inform the reader on the nature of the agrin solution that was used. 
Details concerning e.g. the cultivation of myotubes, which were employed to test the agrin solution, 
will not be explained in this thesis, as neither muscle cells nor muscle cell precursors were used for 
any other experiments.  
Protocol:  
One day before transfection HEK293T cells were plated in a 10 cm dish at a density of 1 x 106 cells/ 
10 cm dish. The cells were transfected with C‐Ag 4.8 (= an expression vector coding for the C‐
terminal half of agrin) as explained in Section 5.5.5.1 for 15 h. To stop the transfection, the medium 
containing the transfection mix was aspirated, the cells were washed with PBS once and OptiMEM + 
1 x Pen/ Strep + 5 % FBS was added (7 mL/ 10 cm dish). The cells were incubated at 37°C to allow 
synthesis of agrin and its secretion into the growth medium. 48h after medium change the growth 
medium was taken off and cells and cell debris were removed from the medium (herein after 
referred to as ‘agrin/ OptiMEM’) by centrifugation at 389 rcf for 5 min. To determine the 
concentration of agrin/ OptiMEM that was required for MuSK‐activation experiments, myotubes 
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were treated with increasing concentrations of the agrin solution and MuSK phosphorylation levels 
were assessed biochemically (see Section 5.6.7). The lowest concentration, at which maximal MuSK 
activation was detected, was used in all further experiments.  
5.5.3 Freezing Cells  
Cells were trypsinized and pelleted by centrifugation at 389 rcf for 4 min. The supernatant was 
aspirated and the cells were resuspended in freezing medium containing DMSO (Table 14), quickly 
transferred to cryotubes (1‐1.5 mL/ tube) and frozen at ‐80°C. If the cells were supposed to be stored 
for a longer period of time they were transferred to liquid N2 tanks 24 h after initial freezing. 
Otherwise they were kept at ‐80°C until further use.  
Table 14| Freezing Medium 
Reagent Concentration 
DMEM  
FBS 20 % 
Pen/Strep 1 x 
DMSO 10 % 
 
5.5.4 Thawing Cells  
If fresh cells were needed a cryotube containing a frozen cell suspension was incubated in a water 
bath at 37°C to ensure quick thawing. As soon as the suspension was nearly completely thawed the 
tube was transferred into the sterile laminar airflow work bench and the cell suspension (approx. 1‐
1.5 mL) was quickly pipetted into 5‐6 mL fresh growth medium. To remove DMSO the cells were 
pelleted by centrifugation at 389 rcf for 4 min, the supernatant was removed and the cells were 
resuspended in fresh growth medium and plated in an appropriate concentration.  
5.5.5 Transient Transfection  
5.5.5.1 CaCl2/ BBS–Transfection  
Reagents:  
Stock solutions were prepared, autoclaved or filter‐sterilized according to Table 15 and stored at RT.  
Table 15| Stock Solutions for CaCl2/ BBS­Transfection 
Solution  Concentration  
CaCl2 (autoclaved or filter‐sterilized)  2.5 M 
NaCl (autoclaved)  5 M 
BES  1 M 
Na2HPO4  1 M 
The stock solutions were used to prepare working solutions 0.25 M CaCl2 and 2 x BBS (Table 16 and 
Table 17). Usually 100 mL of each working solution were prepared, filter‐sterilized in a sterile laminar 
airflow work bench, aliquoted (10 x 10 mL) and stored at ‐20°C.  
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Table 16| Preparation of 0.25 M CaCl2  
Solution Volume  
2.5 M CaCl2  10 mL  
ddH2O (autoclaved)  90 mL  
 
Table 17| Preparation of 2 x BBS  
Solution Volume  
ddH2O (autoclaved)  80 mL  
5 M NaCl  5.6 mL  
1 M BES  5 mL  
1 M Na2HPO4  150 µL  
The pH‐value of the working solution was adjusted to 6.95 
± 0.02 with HCl.  
ddH2O  adjusted to 100 mL 
15‐30 min before use aliquots of the working solutions were thawed in a water bath at RT.  
Protocol:  
For the number of plated cells, volumes of 0.25 M CaCl2, 2 x BBS and growth medium and amounts of 
DNA required for individual dish sizes see Table 18.  
Preparation of cells: One day before transfection cells were trypsinized and plated in defined cell 
number in normal growth medium. The volume of growth medium in the culture dish was adjusted 
depending on the dish size.  
Transfection: DNA was pipetted into a 4mL sterile culture tube. 0.25 M CaCl2 was added drop wise 
and the solution was mixed by snipping against the tube. 2 x BBS was added drop wise under 
vortexing and the mix was incubated at RT for 13‐15 min to allow DNA/ Ca3(PO4)2 precipitates to 
form. Following incubation the transfection mix was pipetted drop wise into the growth medium and 
the cells were incubated at 37°C, 5 % CO2 for 8 h (over day‐transfection) or 15 h (over night‐
transfection). Finally the supernatant (growth medium + DNA/ CaCl2/ BBS) was aspirated from the 
dish, fresh growth medium was added and the cells were incubated at 37°C, 5 % CO2 for 24 h.  
(In case that more than one transfection was performed in parallel, first DNA was pipetted into all 
tubes. Then CaCl2 was added to all tubes. A timer was started and 2 x BBS was added to the tubes 
one after the other in equal time intervals of e.g. 30 sec. Addition of the mixtures to the plates was 
performed 13 min after addition of 2 x BBS to the first tube in the same time intervals. ) 
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Table 18| CaCl2/ BBS­Transfection: Volumes and Amounts of Reagents Required for Distinct Dish Sizes 
Dish Size  Cell Number Growth 
Medium  
DNA  0,25 M CaCl2  2 x BBS  
10 cm   0.8 ­ 1.0 x 106  10 mL   20 µg   875 µL   875 µL  
6 cm   0.4 ­ 0.5 x 106  5 mL   10 µg   437.5 µL   437.5 µL  
1 well  
(6­well plate) 
0.7 ­ 1.0 x 105  2 mL   4 µg   175 µL   175 µL  
1 well  
(12­well plate)  
cells were plated on 
coverslips in a 10cm dish  
(0.8 ­ 1.0 x 106/ 10 cm 
dish, ~12 coverslips/ 
10 cm dish) 
1. 7 mL   3 µg   145 µL   145 µL  
 
5.5.5.2 Turbofect­Transfection  
Reagents:  
Table 19| Reagents for Turbofect­Transfection 
Reagent  Supplier 
TurbofectTM in vitro Transfection Reagent *  Fermentas 
OPTI­MEM I + GlutaMAXTM­I (1 x)**  GIBCO invitrogen 
DMEM with 4.5 g/L Glucose with L­Glutamine   LONZA 
* further called Turbofect, ** further called OPTI­MEM 
Protocol:  
For  the  the  number  of  plated  cells,  the  volumes  of  DMEM,  OptI­MEM  and  Turbofect  and  the 
amounts of DNA required for individual dish sizes see Table 20.  
Preparation of cells: One day before transfection cells were trypsinized and plated in defined number 
in  normal  growth medium.  Shortly  before  transfection,  growth medium was  aspirated,  cells were 
washed with PBS once and the appropriate volume of DMEM was added.  
Transfection: DNA was pipetted into a 4mL sterile culture tube. OPTI­MEM was added drop wise and 
the solution was mixed briefly by snipping against the  tube. Turbofect was added and  the mixture 
was again mixed thoroughly. The transfection mix was incubated at RT for 17.5 min and then added 
to the cell culture dish drop wise. The cells were incubated at 37°C, 5 % CO2 for 3h to allow uptake of 
DNA.  (If  the  transfection  efficiency  was  found  to  be  low  and  the  cells  were  not  too  sensitive  to 
Turbofect­treatment  the  incubation  time  was  prolonged.)  Following  incubation,  the  supernatant 
(DMEM  +  DNA/  OPTI­MEM  /Turbofect)  was  aspirated  from  the  dish,  the  cells  were  washed  with 
growth  medium  once  and  then  incubated  in  fresh  growth  medium  at  37°C,  5 % CO2  for  20­24 h 
(herein after referred to as ‘medium change’). 
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Table 20| Turbofect­Transfection: Volumes and Amounts of Reagents Required for Distinct Dish Sizes 
Dish Size  Cell Number DMEM  DNA  OPTI­MEM  Turbofect  
6 cm   0.4 ­ 0.5 x 106  6 mL   10 µg   900 µL   7.5 µL  
1 well  
(6­well plate) 
0.7 ­ 1.0 x 105  4 mL   6 µg   600 µL   5 µL  
1 well  
(12­well plate)  
cells were plated on coverslips in 
a 10cm dish (0.8 ­ 1.0 x 106/ 
10 cm dish, ~12 coverslips/ 
10 cm dish) 
2 mL   3 µg   300 µL   2.5 µL  
 
5.5.6 Stable Transfection  
Stable  transfections  of  COS­7  and HeLa  cells were  performed.  Phoenix  A  cells were  used  as  virus 
particle producer cells. The target cells were infected twice to increase the transfection efficiency. To 
create negative controls Phoenix A cells were transfected with CaCl2/ BBS­mix without DNA. Hence, 
these Phoenix A cells shouldn’t be able to produce virus particles. The supernatant of the cells was 
used for the ‘infection’ of negative control cells. Negative controls should therefore not be resistant 
to selection reagent.  
Preparation  of  producer  cells  (Day  0):  One  day  before  transfection  Phoenix A  cells were  split  and 
plated in 10cm dishes, 1.1 x 106 cells/ 10 cm dish.  
Transfection of producer cells (Day 1 & 2): Phoenix A cells were transfected with plasmid via CaCl2/ 
BBS­Transfection  o/n  for  15 h  as  explained  in  Section  5.5.5.1.  On  Day  2  the  medium  of  the 
transfected  Phoenix  A  cells  was  aspirated  and  the  cells  were  incubated  in  fresh  growth  medium 
(7 mL/ 10 cm dish). 
Preparation of target cells (Day 2): Target cells for stable transfections (COS­7, HeLa) were plated in 
6­well plates, 0,7 x 105 cells/ well.  
Harvest of virus particles and first infection of target cells (Day 3):  
Harvest: 24 h after medium change the supernatant containing virus particles was aspirated from the 
producer cells and transferred to a 15 mL Falcon tube. Fresh growth medium was added to producer 
cells and cells were incubated at 37°C, 5 % CO2 for further 24 h. To remove cell debris the harvested 
supernatant was centrifuged at 1559 rcf for 10 min and transferred to a fresh Falcon tube.  
Infection: The growth medium of the target cells was aspirated and the supernatant harvested from 
the producer cells (1.5 mL/ well of a 6­ well plate) mixed with polybrene (5 µg/mL) were added. Cells 
were  centrifuged at  18 rcf,  32°C  for  1 h,  and  incubated at  37°C, 5 % CO2  for  further  5 h.  Then  the 
supernatant was  removed,  the  cells were washed with PBS once and  incubated  in normal growth 
medium, 37°C, 5 % CO2 o/n (herein after referred to as ‘medium change’).  
Harvest  of  virus  particles  and  second  infection  of  target  cells  (Day  4):  Harvest  and  Infection were 
repeated as explained for Day 3. Phoenix A producer cells were discarded after the second harvest.  
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Start of selection (Day 5 & 6): More than 24 h after the last medium change the infected target cells 
were  split  to  10 cm  dishes  and  incubated  in  growth  medium  containing  the  selection  reagent 
puromycin (starting concentrations: COS­7: 2 µg/mL, HeLa: 1 µg/mL).  
Cultivation  (After  Day  6):  Control  cells  stopped  growing  two  to  three  days  after  the  start  of 
puromycin  treatment  if puromycin  treatment was selective enough. After several days of  selection 
the  puromycin  concentration  was  decreased  to  reduce  cellular  stress  (COS­7:  1.0 µg/mL,  HeLa: 
0.5 µg/mL). 
5.5.7 Agrin­Stimulation  
Normal growth medium was removed and the cells were washed with PBS once. In order to deprive 
the cells of nutrients and make them more sensitive to agrin, the cells were incubated in a defined 
volume of DMEM (Table 21) at 37°C, 5 %CO2 for 3 h. Following this ‘starvation’, agrin/ OptiMEM was 
added in the tested concentration (see Section 5.5.2) and the cells were incubated at 37°C, 5 % CO2 
for another 30 min to 1 h.  
Table 21| Starvation: Volume of DMEM required for different dish sizes 
Dish size  DMEM  
10 cm  4 mL  
6 cm  2 mL  
 
Starvation  of  transiently  transfected  cells  was  started  20 h ­ 20.5 h  after  medium  change  to  allow 
lysis of cells 24 h after medium change.  
5.5.8 Antibody­Mediated Stimulation of MuSK 
Cells  were  transfected  with  an  N­terminally  tagged  MuSK  construct  (HA­MuSK,  Myc­MuSK)  as 
explained in Section 5.5.5.1 over day for 8 h. The cells were starved as explained for agrin­stimulation 
in 5.5.7 for 3 h, starting 20 ­ 20.5 h after medium change. 3 mL instead of 4 mL DMEM was added per 
10 cm dish to reduce the amount of required antibody in the next step. In order to activate MuSK 50­
100 nM antibody (= 7.5 ­ 15 µg/mL) specific for the N­terminal tag of the used MuSK variant (anti­HA, 
anti­c­Myc) was added and cells were incubated at 37°C, 5 % CO2 for 30 min ­ 1 h. Cells were lysed as 
explained in Section 5.6.1 24 h after medium change.  
5.5.9 Immunocytochemistry  
5.5.9.1 Conventional Immunocytochemistry  
(Transfection:  For  detection  of  heterologously  expressed  proteins  cells were  transfected  with  the 
protein(s)  of  interest  via  CaCl2/ BBS­  or  Turbofect­transfection  as  explained  in  Section  5.5.5  and 
immunocytochemical stainings were performed 20 ­ 24 h after medium change.) 
Washing: Growth medium was aspirated and the cells were carefully washed with cold PBS 3 times 
(3 x). 
Fixation: To fix the cells they were incubated in 4 % PFA at RT for 10 min. 
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Permeabilization: Permeabilization was achieved by incubation of the cells in 0.1 % Triton/PBS at RT 
for 5 min. (This step was skipped, if only surface protein should be stained.) 
Washing: The cells were washed 3 x by incubation in PBS (RT) for 5 min.  
Blocking:  To  block  unspecific  binding  sites,  the  permeablized  or  unpermeabilized  cells  were 
incubated in 10 % FBS/ PBS at RT for 20 min.  
Primary antibody: The protein of  interest was detected by  incubating  the cells  in primary antibody 
dilution at RT for 1 h. For this purpose, the coverslips were put upside down on droplets of 20 µL of 
antibody­dilution. Subsequently the coverslips were washed by dipping into PBS 3 x.  
Secondary  antibody:  Bound  primary  antibody  was  detected  by  incubating  the  cells  in  secondary 
antibody  dilution  (anti­rbt­Cy3,  1:800  in  10 %  FBS/PBS)  as  explained  for  the  primary  antibody 
incubation at RT for 45 min. Subsequently the coverslips were washed by dipping into PBS 3 x.  
Mounting:  The  coverslips were mounted on  glass  slides  and  the  surplus  of mounting medium was 
carefully  aspirated  (avoiding moving  of  the  coverslip)  to  ensure  that  the  coverslips  were  pressed 
tightly onto  the  glass  slide. Mowiol was used as mounting medium. The mounted  coverslips were 
kept at RT in the dark for 1 h to allow the mounting medium to harden. Afterwards the glass slides 
were stored at 4°C in the dark to be analyzed via fluorescence or confocal fluorescence microscopy.  
5.5.9.2 Surface Protein Internalization Assay (Streptavidin)  
Streptavidin incubation: Living cells were starved by incubation in cold DMEM at 4°C for 30 min and 
then incubated with fluorophore­coupled streptavidin diluted 1:1000 in DMEM without supplements 
(cold!) at 4°C  for  further 30 min  (280 µL/ well of 12­well plate). The cells were washed once  ­ with 
cold  PBS  if  the  cells  were  immediately  used  for  fixation  or  in  normal  GM  if  internalization  was 
allowed in the next step. (For this purpose, the coverslips were transferred from the 12­well plate to 
pre­chilled 3.5 mm dishes containing cold PBS or cold, normal GM. The 12­well plate and the 3.5 mm 
dishes were  kept  on  ice  during  the whole  procedure.  PBS  or  GM was  aspirated  from  the  3.5 mm 
dishes and replaced depending on the next step. If the cells should exhibit no internalization – in the 
case of time point 0min and stripping positive and negative controls– the cells were directly subject 
to fixation after this step.) 
Internalization: After washing, the cells were incubated in normal GM at 37°C to allow internalization 
of surface proteins. The internalization was stopped at defined time points by putting the dishes on 
ice and washing them with cold PBS 3 x. (Commonly tested durations of  internalization were 5, 15, 
30, 60 and 120 min.) 
Fixation, permeabilization and further stainings were performed as explained in Section 5.5.9.1.  
5.5.9.3 Surface Protein Internalization Assay (Antibody)  
(The protocol was adapted from (Sharma et al., ; Tanowitz and von Zastrow, 2003) and (Cao et al., 
1999).) 
Primary antibody incubation (Step #1): Living cells were incubated with anti­HA (rbt, Sigma) diluted 
1:100  in  DMEM without  supplements  (cold!)  at  4°C  for  20min  (280 µL/ well  of  12­well  plate).  The 
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cells were washed once ­ with cold PBS if the cells were immediately used for stripping and fixation 
or in normal GM if internalization was allowed in the next step. (For this purpose, the coverslips were 
transferred from the 12­well plate to pre­chilled 3.5 mm dishes containing cold PBS or cold, normal 
GM. The 12­well plate and the 3.5 mm dishes were kept on ice during the whole procedure. PBS or 
GM was  aspirated  from  the  3.5 mm dishes  and  replaced  depending  on  the  next  step.  If  the  cells 
should exhibit no internalization – in the case of time point 0 min and stripping positive and negative 
controls– the cells were directly subject to stripping (Step #3) after this step.) 
Internalization  (Step  #2):  After  washing,  the  cells  were  incubated  in  normal  GM  at  37°C  to  allow 
internalization of surface proteins. The internalization was stopped at defined time points by putting 
the  dishes  on  ice  and  washing  them  with  cold  PBS  once.  (Commonly  tested  durations  of 
internalization  for  the proteins HA­MuSK, HA­MuSK­Ubwt and HA­MuSK­Ubmut were 5, 15, 30, 60 
and 120 min.)  
Antibody Stripping (Step #3): To detach primary antibody from surface protein not internalized in the 
previous step, the cells were incubated in cold PBS (pH 2.5) (stripping buffer) on a shaker, shaking at 
moderate speed, 2 x for 4 min. The stripping buffer was changed after the first 4 min. After stripping, 
the cells were washed with cold PBS 3 x to remove the stripping buffer. 
(If  stripping wasn’t  desired  –  in  case  of  “stripping  negative  control”  for  example  –  the  cells were 
treated with PBS (pH­neutral) instead of PBS (pH 2.5) for 2 x 4 min.)  
Fixation  (Step #4): To  fix  the cells,  they were  incubated  in 4 % PFA at RT for 10 min.(The  following 
step was  skipped,  if  permeabilization wasn’t  intended  at  this  stage  –  e.g.  in  the  case  of  stripping 
positive and negative control.) 
Permeabilization & Blocking  (Step #5):  Permeabilization was achieved by  incubation of  the  cells  in 
0,1% Triton/ PBS at RT  for  5min. Afterwards  the cells were washed with PBS (RT) 3 x  for 5min. To 
block unspecific binding sites permeabilized cells were incubated in 10% FBS/ PBS at RT for 20min.  
Secondary  antibody  (Step  #6):  Anti­HA  antibody  bound  to  internalized  protein  was  stained  by 
incubating  cells  in  secondary  antibody  dilution  (anti­rbt­Cy3,  1:800  in  10 %  FBS/ PBS)  at  RT  for 
45 min.  For  this,  coverslips  were  put  upside  down  on  droplets  of  20 µL  of  antibody­dilution. 
Subsequently coverslips were washed by dipping into PBS 3 x.  
Permeabilization and Blocking (Step #1a): see Step#5  
Primary  antibody  (Step  #2a):  Total  protein  of  interest was  detected  by  incubating  cells  in  primary 
antibody dilution (anti­HA (rbt), 1:100 in 10 % FBS/PBS) as explained in Step#6 but for 1h.  
Secondary antibody (Step #3a): Anti­HA antibody bound to total protein of  interest was stained by 
incubating  cells  in  different  2nd  antibody  dilution  than  in  Step#6  (anti­rbt­488,  1:500  in  10 % 
FBS/ PBS) as explained in Step #6 .  
Mounting (Step #7): Coverslips were mounted on glass slides and surplus of mounting medium was 
carefully aspirated (avoiding moving of coverslip) to ensure that coverslips were pressed tightly onto 
the glass slide. Mowiol was used as mounting medium. Mounted coverslips were kept at RT  in  the 
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dark for 1 h to allow the mounting medium to harden. Then glass slides were stored at 4°C in the 
dark to be analyzed via fluorescence or confocal fluorescence microscopy.  
Table 22| Scheme 1 for sample antibody internalization­experiment 
Coverslip # Name Description 
1 stripping 
neg. control  
cells transfected with protein of interest and treated with primary 
antibody after 0 min of internalization (no internalization), not subject 
to antibody stripping, not permeabilized 
2 stripping 
pos. control  
cells transfected with protein of interest and treated with primary 
antibody after 0 min of internalization (no internalization), subject to 
antibody stripping, not permeabilized 
3 timepoint 
0 min 
cells transfected with protein of interest and treated with primary 
antibody after 0 min of internalization (no internalization) 
4 timepoint 
0 min 
cells transfected with protein of interest and treated with primary 
antibody after 5 min of internalization  
5 timepoint 
0 min 
cells transfected with protein of interest and treated with primary 
antibody after 15 min of internalization  
6 timepoint 
0 min 
cells transfected with protein of interest and treated with primary 
antibody after 30 min of internalization  
7 timepoint 
0 min 
cells transfected with protein of interest and treated with primary 
antibody after 60 min of internalization  
8 timepoint 
0 min 
cells transfected with protein of interest and treated with primary 
antibody after 120 min of internalization  
9 negative 
control  
untransfected cells treated with secondary but not with primary 
antibody, duration of internalization step not relevant, as no antibody 
can be internalized 
 
Table 23| Scheme 2 for sample antibody internalization­experiment 
coverslip#\step (transfection 
with protein 
of interest) 
#1  
antibody 
incubation 
 
#2  
internalization 
#3 
antibody 
stripping  
#4 
fixation 
#5 
permeabilization 
& blocking 
#6 
secondary 
antibody  
 
1 + + ‐ ‐ + ‐ +  
2 + + ‐ + + ‐ +  
3 + + ‐ + + + +  
4 + + 5min + + + +  
5 + + 15min + + + +  
6 + + 30min + + + +  
7 + + 60min + + + +  
8 + + 120min + + + +  
9 ‐ ‐ optional + + + +  
 
Coverslips ‘stripping negative control’ and ‘stripping positive control’ should demonstrate the 
efficiency of antibody stripping. The cells on the two coverslips were not permeabilized. After 
incubation of the living cells on the coverslips in primary antibody, ‘stripping positive control’ was 
subject to Step #3, antibody stripping, by which all bound antibody should be detached from the 
target protein on the cell surface. ‘Stripping negative control’ was treated with PBS 2 x for 4 min 
instead of stripping reagent. The primary antibody should remain bound to surface target protein. 
After fixation, the cells were not permeabilized. Therefore only surface‐bound primary antibody 
should be stained in the subsequent staining with fluorophore 1‐coupled secondary antibody (, in 
this case anti‐rbt‐Cy3). However, target protein‐positive but successfully stripped cells would now 
not be possible to discriminate from untransfected cells anymore. As a consequence it was necessary 
to identify target protein‐positive cells in a second round of staining. Following the surface staining, 
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cells were therefore permeabilized, blocked and treated with the same primary antibody as in the 
first round of staining (anti‐HA (rbt)). This time the antibody should bind all free epitopes on the cell 
surface as well as intracellular target protein. Incubation with secondary antibody carrying a different 
fluorophore 2 (in this case anti‐rbt‐488) should bind this primary antibody and should make it 
possible to discriminate between anti‐HA antibody bound in the first and second round of staining. If 
stripping has been successful, on the ‘stripping positive control’ HA‐tag‐positive cells identified in the 
second staining should exhibit no specific fluorophore 1‐staining originating from the first staining 
round. Contrarily, HA‐tag‐positive cells on the ‘stripping negative control’ should show clear surface 
staining for fluorophore 1.  
5.6 Molecular Biology  
5.6.1 Cell Lysis  
Cells were placed on ice and washed with cold PBS three times. Then appropriate volume (see Table 
26) of lysis buffer containing protease inhibitors, RIPA‐buffer + inhibitors or NP‐40‐buffer + inhibitors, 
was added. (As protease inhibitors are not stable after dilution in lysis buffer, the inhibitors were 
added only shortly (~10 min) before washing of the cells was started. For this purpose, the required 
volume of lysis buffer was aliquoted and inhibitors were added according to their recommended 
dilution factor as listed in Table 27. PMSF was added last, the mixture was vortexed immediately 
afterwards and put on ice until use.) The dishes were incubated on a shaker at moderate speed, at 
4°C, for 25 ‐ 30 min. Following incubation, the cells were scraped from the dish with a rubber scraper 
and the lysate was transferred to a prechilled 1.5 mL Eppendorff tube. Cell debris was pelleted by 
centrifugation at 16,100 rcf for 10 min. The supernatant (=lysate) was transferred to a fresh tube and 
was used directly for immunoblotting, subject to immunoprecipitation (Section 5.6.3) or pull‐down 
(5.6.4) or frozen in liquid N2 and stored at ‐20 or ‐80°C.  
Table 24| RIPA­Buffer  
Reagent  Concentration  
Tris‐HCl (pH 7,5)  50 mM  
NaCl  150 mM  
NP‐40  1 % (v/v)  
Na‐Desoxycholat  0,5 % (w/v)  
NaF  50 mM  
 
Table 25| NP­40­Buffer 
Reagent  Concentration  
NP40 1 % 
EGTA  5 mM  
NaCl 50 mM 
TEA pH 7.5 30 mM 
NaF 50 mM 
 
Table 26| Volume of lysis buffer required for individual dish sizes  
Dish size Volume  
10 cm dish  600 µL  
6 cm dish 250‐300 µL  
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Table 27| Proteinase Inhibitors – Stock Solutions and Dilution Factor for Use in Cell Lysis  
Inhibitor MW (g/mol) Stock Concentration  diluted in Dilution Factor for 
Working Concentration 
Pepstatin   0.5 mg/mL EtOH* 1:500 
Leupeptin   1 mg/mL dH2O  1:1000 
Aprotinin  1 mg/mL dH2O  1:1000 
Sodium 
Orthovanadate  
183.9 200 mM dH2O** 1:200 
PMSF   100 mM EtOH  1:500 
* Inhibitor was dissolved o/n on a shaker. The flask was covered with aluminum foil as the compound 
is light sensitive.  
** 1.47 g powder was dissolved in 30 mL dH2O first and the pH was adjusted with HCl (diluted 1:2 in 
dH2O) to pH 10. (� Then the solution turned yellow.) The solution was boiled until it turned clear 
again. It was aliquoted and aliquots were frozen at ‐80°C. 
5.6.2 Preparation of Total Aliquots for Immunoblotting  
If cell lysates (as prepared according to Section 5.6.1) should be analyzed directly via SDS‐PAGE and 
immunoblotting 4 x SDS loading dye was added 1:4 to a defined volume of lysate. Commonly 40 µL 
total aliquot sample (30 µL lysate + 10 µL 4 x SDS loading dye) were sufficient to yield strong signals 
in immunodetection. For weakly expressed proteins up to 70 µL of total aliquot sample were loaded. 
(The volume of 70 µL was chosen as it represented the maximum volume that could be conveniently 
pipetted into one slot of a 1.5 mm PAGel with 10 slots.) 
5.6.3 (Co­)Immunoprecipitation  
Background Information:  
Immunoprecipitation yields at concentrating a specific protein from a cell lysate. For this purpose the 
lysate is incubated with a protein‐specific antibody. The resulting protein‐antibody complexes are 
precipitated with agarose beads, which bind antibodies independently from their specificity. For 
untagged proteins antibodies against protein‐intrinsic epitopes were applied. Tagged proteins were 
in general immunoprecipitated by the use of tag‐specific antibodies.  
Co‐immunoprecipitation is performed in a similar way as immunoprecipitation but with the goal not 
only to purify a single protein but complexes of two or more proteins. In order to avoid dissociation 
of complexes it can be necessary to reduce stringency (salt or detergent concentration) in the 
procedure by adaptation of lysis buffers. 
Protocol:  
Cells were lysed as explained in Section 5.6.1. Antibody was added according to Table 28 and the 
lysate/ Ab‐mix was incubated at 4°C, end‐to‐end rotating, o/n to allow the antibody to bind its target 
protein. The next day, protein A or protein G agarose beads were added and the lysates were 
incubated for an additional hour at 4°C, end‐to‐end rotating during which agarose beads was allowed 
to bind the antibody.  
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To remove unbound protein from agarose beads, the beads were washed with lysis buffer. (In the 
case of normal immunoprecipitation the same lysis buffer, RIPA‐buffer + inhibitors, was used for lysis 
and washing. For co‐immunoprecipitation NP‐40‐buffer + inhibitors, 50 mM NaCl, was used during 
lysis. For washing of beads the same buffer was used, but the concentration of NaCl was increased to 
150 mM.) Lysate containing beads was centrifuged at 16,100 rcf for 2 min. The supernatant was 
taken off except for approximately 100 µL. 1mL lysis buffer + inhibitors was added and tube was 
inverted 5 ‐ 10 x. The beads were again pelleted by centrifugation at 16,100 rcf for 2 min. This step 
was repeated twice. After the third washing, the beads were pelleted and the supernatant was taken 
off so that only approximately 30 µL buffer were left in the tube. 10 µL 4 x SDS loading dye were 
added, sample was mixed and used directly for immunoblotting or stored at ‐20 or ‐80°C.  
Table 28| Antibodies for (Co­)IP  
Antibody  Dilution Factor  
Anti‐HA antibody produced in rabbit 1:200 
Monoclonal ANTI‐c‐MYC clone 9E10 1:1000  
 
5.6.4 (Co­)Pull­Down  
Background Information:  
Pull‐down (PD) and co‐pull‐down (Co‐IP) are also methods aiming at purifying a protein (PD) or 
protein complexes (Co‐PD) from a total cell lysate. However, in contrast to IP or Co‐IP, in PD and Co‐
PD one takes advantage of the strong natural interaction between streptavidin‐binding protein (SBP) 
and streptavidin. Upon co‐incubation the two proteins form a strong complex. This makes it possible 
to purify SBP‐tagged proteins from cell lysates with streptavidin‐coupled agarose beads. No tag‐ or 
protein‐specific antibody is required.  
Protocol:  
Cells were lysed as explained in Section 5.6.1. 20 µL streptavidin agarose beads were added per 
sample and the mix was incubated at 4°C, end‐to‐end rotating, o/n to allow streptavidin and the SBP‐
tag to interact and bind.  
The next day the beads were washed with lysis buffer to remove unbound proteins. Washing was 
performed as explained for immuno‐ and co‐immunoprecipitation (Section 5.6.3) . After the third 
washing, the beads were pelleted and the supernatant was taken off so that only approximately 
30 µL buffer were left in the tube. 10 µL 4 x SDS loading dye were added, the sample was mixed and 
used directly for immunoblotting or stored at ‐20 or ‐80°C.  
5.6.5 SDS­PAGE and Immunoblotting  
Resolving gels with a concentration of acrylamide/bisacrylamide according to the size of the analyzed 
protein were prepared. They were overlaid with 5 % stacking gels 
4 x SDS PAGE sample buffer was added to the samples (in a dilution of 1:4). To denature and linearize 
the proteins the samples were incubated at 95°C for 5 min.  
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The samples were loaded onto PAGels next to 5 µL of protein size standard. As size standard Page 
Ruler Prestained Protein Ladder #SM0671 (Fermentas) was used. Gel electrophoresis was performed 
at 70‐130mV in Running Buffer using the Mini Protein III gel electrophoresis system (BioRad).  
After electrophoresis, the gels were blotted onto a PVDF membrane at 50 mA/ 1 gel (~1.01 mA/cm2) 
for 85 min in transfer buffer using the Trans‐Blot® SD Semi‐Dry Transfer Cell blotting system (BioRad).  
If a blot needed to be cut vertically between lanes, it was in general stained reversibly with Ponceau 
solution to visualize protein bands and thus lanes. For this purpose, the membrane was incubated in 
Ponceau solution for 2 ‐ 3 min and washed with dH2O until the lanes were clearly visible. The 
membrane was cut and destained in TBS‐T.  
To prevent unspecific binding of antibody the blots were incubated in 5 % milk powder/TBS‐T for 1 h 
or in 5 % BSA/TBS‐T for 2 h or o/n. After blocking with milk, the blots were washed 3 x for 10 min in 
order not to contaminate the primary antibody solution with milk. Blots blocked in BSA were not 
washed as primary antibodies were in general diluted in 5% BSA. The blots were transferred to 
primary antibody solution and incubated at 4°C, shaking, o/n. The next day, the immunoblots were 
washed with TBS‐T 3 x for 10 min and incubated in HRP‐coupled secondary antibody (anti‐rbt‐HRP or 
anti‐ms‐HRP diluted 1:5000 in 5 % Milk/ TBS‐T for 1 h at RT. (For each staining fresh secondary 
antibody‐dilution was prepared.) Following incubation, the blots were washed with TBS‐T 3 x for 
10 min, dipped dry and placed on a glass plate. They were covered with Lumi‐Light Western Blotting 
Substrate (Roche) (about 1.0 mL per membrane, =~51 cm2) and incubated for 5 min. Then the 
solution was poured off and the blots were put into a transparency and developed in a Fluor‐S 
Multiimager (BioRad) using Quantity One 4.4.1 detection software (BioRad).  
 
Table 29| Running Gel Buffer (pH ~8.8*) 
Reagent  Concentration  
Tris  1.5M 
HCl  0.25M 
*pH‐value wasn’t adjusted but checked 
Table 30| Stacking Gel Buffer (pH ~6.8*)  
Reagent  Concentration  
Tris  0.02M 
Tris‐Cl 0.48M 
*pH‐value wasn’t adjusted but checked  
Table 31| Running Gel (1 Gel, 1.5 mm Thickness)  
 Concentration [Acrylamide] 
Reagent  7.5 %  10 %  12.5 %  
40 % acrylamide mix  1.88 mL  2.5 mL  3.1 mL  
1.5 M Tris / 0.25M HCl 2.5 mL  2.5 mL  2.5 mL  
dH2O  5.4 mL  4.8 mL  4.2 mL  
10 % SDS (w/v) 100 µL  100 µL  100 µL  
10 % APS (w/v) 50 µL  50 µL  50 µL  
TEMED  10 µL  10 µL  10 µL  
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Table 32| Stacking Gel (1 Gel, 1.5 mm thickness)  
 Concentration  
Reagent  5 %  
40 % acrylamide mix  0.625 mL  
1.5 M Tris / 0.25 M 
HCl 
1.25 mL  
dH2O  3.025 mL  
10 % SDS (w/v) 50 µL  
10 % APS (w/v) 50 µL  
TEMED  5 µL  
 
Table 33| 5 x Running Buffer Stock Solution  
Reagent  Amount  Concentration  
Tris  15.05 g 0.12 M  
Glycine  72 g  0.96 M 
SDS  5 g  0.017 M 
dH2O  adjusted to 1 L   
To prepare a 1 x working solution the 5 x running buffer stock solution was diluted 1:5 in dH2O.  
Table 34| 10 x Transfer Buffer Stock Solution  
Reagent  Amount  Concentration  
Tris  58 g  0.48 M 
Glycine  29 g  0.39 M 
SDS  5 g  0.017 M 
dH2O  adjusted to 1 L   
To prepare a 1 x working solution the 10 x stock solution was diluted 1:10 in 10% Methanol / dH2O.  
Table 35| 10 x TBS­Tween Stock Solution 
Reagent  Concentration  
10 x/ 1 x  
1 M Tris­Cl pH 8 100 mM / 10 mM 
NaCl  1.5 M / 0.15 M  
Tween  0.5 % / 0.05 %  
To prepare a 1 x working solution the 10 x stock solution was diluted 1:10 in dH2O. 
5.6.6 Stripping of an Immunoblot after Development 
To remove remaining immunoblotting substrate solution after development, the membrane was 
washed by shaking in dH2O for 5 min. Secondary antibodies were stripped from the blot by shaking in 
0.2 M NaOH/dH2O for 5 min and the blot was washed in dH2O for further 5 min. Following this 
‘stripping’ the blot was stored in TBS­T at 4°C or used directly for another round of detection. In this 
case the blot was again blocked in 5 % BSA/ TBS­T or 5 % Milk/ TBS­T previous to incubation in 
primary antibody.  
5.6.7 Biochemical Quantification of MuSK Tyrosine Phosphorylation  
IP or PD samples containing MuSK were resolved via SDS­PAGE and transferred onto a PVDF 
membrane as described in Section 5.6.5. After blocking of the membrane with 5 % BSA/TBS­T for 2 h 
at RT the blot was incubated in anti­pTyr at 4°C, shaking, o/n and developed the following day. Then 
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the blot was stripped with NaOH (Section 5.6.6), again blocked with 5 % BSA/TBS­T and probed for 
MuSK with an antibody against MuSK (anti­MuSK C.F) or against the tag of the respective construct 
used in this experiment (e.g. anti­HA for MuSK­HA). Chemiluminescence of pTyr­signals 
corresponding in molecular mass with MuSK (pTyr  (MuSK)) and specific MuSK­signals (MuSK) were 
quantified for all individual samples and pTyr  (MuSK)/MuSK ratios were calculated.  
5.6.8 Analysis of Protein Stability in COS­7 Cells 
Reagents:  
Cycloheximide stock solution: 10mg/mL  
To prepare the stock solution, 15 mg cycloheximide were diluted in 1.5 mL sterile ddH2O. The 
solution was aliquoted and the aliquots were stored at 4°C.  
Protocol:  
COS­7 cells were transfected via CaCl2/ BBS­transfection with the gene of interest and a vector 
coding for EGFP­N2, which was used as internal standard. The transfection was performed over day 
for 8 h as explained in Section 5.5.5.1. Cells were lysed with RIPA­buffer with inhibitors 23 ­ 24 h after 
medium change as explained in Section 5.6.1. To analyze the protein half­life transfected cells were 
treated with 50 µg/mL cycloheximide for certain periods of times before lysis. The reagent blocks 
ribosomal protein synthesis and therefore prevents new protein from being produced whilst the pool 
of protein already present in the cells at the beginning of inhibition is degraded according to its 
stability. The degradation process can be assessed by quantification of the amount of the protein of 
interest relative to the amount of a standard protein of longer half­life than the duration of 
cycloheximide treatment. EGFP­N2 was chosen as internal standard for its high stability of more than 
24 h ((Barrow et al., 2005)).  
���� � � �������������� � 100� ��������������  
5.6.9 Cloning  
5.6.9.1 Enzymatic Restriction  
For enzymatic restriction of purified DNA Fermentas restriction enzymes and corresponding buffers 
were used. If double digests were required a restriction enzyme buffer yielding 50­100 % activity for 
either of the two restriction enzymes was chosen. If none such buffer was available the restriction 
was performed in two subsequent steps. In between either step the buffer concentration was 
adapted (e.g. from 2 x Tango buffer to 1 x Tango).  
5.6.9.2 DNA Purification after Enzymatic Restriction  
Digested DNA was resolved on an agarose­gel of an agarose concentration that yielded optimal 
separation of desired restriction fragments. (Commonly 0.8 % agarose gels were used for fragments 
ranging from 100 ­ 6000 bp. Larger fragments were separated on gels of 0.6 ­ 0.7 % agarose 
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concentration.) DNA bands of interest were cut out and DNA was eluted from the agarose gel blocks 
with GeneJET Gel Extraction Kit (Fermentas) according to the corresponding protocol.  
5.6.9.3 DNA Ligation  
Purified vector and insert DNA, ligase buffer and ligase were mixed according to Table 36.  
Table 36| Ligation mix 
Reagent Amount  
vector  50 ng 
insert  x ng 
T4 ligase buffer (10 x)  2 µL  
T4 ligase  1 µL  
ddH2O  adapted to 20 µL 
total volume 20 µL  
 
The required amount of insert DNA was calculated as follows:  
���������� �  ����������� ���������� � 3���������� �  50�� � ���������� � 3����������  
The ligation mix was incubated for 1 ­ 2 h at RT and then directly used for the transformation of 
competent bacteria or stored at ­20°C.  
5.6.9.4 Cloning of SBP­MuSK­K608A and SBP­MuSK­LS745/746MT 
Kinase­active and kinase­inactive MuSK phosphorylation mutants had been kindly provided by S. 
Burden and had been used by S. Luiskandl to clone variants with fourfold SBP­tags (unpublished 
data). These plasmids were used to create similar constructs with double SBP­tags (Figure 24).  
 
SBP­MusK­K608A 
SacII 
SacII 
BglII 
BglII 
MuSK (1374-2498 bp) 
…CMV­Promoter 
…SBP(2x)­tag 
K608A 
SBP­MusK­
LS745/746MT 
SacII 
SacII 
BglII 
BglII 
MuSK (1374-2498 bp) 
LS745/746MT 
start 
stop stop 
start 
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Figure 24| Cloning of SBP­MuSK Mutants The SBP­MuSK (wt) expression vector was enzymatically restricted 3’ to the SBP 
coding sequence in the MuSK gene and 5’­terminal to the MuSK stop codon. The coding sequence in between was excised 
and replaced by the corresponding portion of MuSK­K608A or MuSK­LS745/746MT respectively. SBP(2x)­tag … double SBP­
tag 
5.6.9.5 Cloning of HA­MuSK­Ubwt and HA­MuSK­Ubmut  
MuSK­Ubwt and MuSK­Ubmut chimeras created by R. Herbst (unpublished data) were cloned into a 
eukaryotic expression vector and provided with an N­terminal HA­tag.  
 
Figure 25| Cloning of HA­MuSK­Ub chimeras HA­MuSK­Ubwt & HA­MuSK­Ubmut CMV/HA­MuSK was enzymatically 
restricted after the 3’­terminus of the MuSK coding sequence and within the sequence coding for the extracellular part of 
MuSK. The resulting fragment was removed and replaced with fragments excised from vectors pLitmus 29/ MuSK­Ubwt and 
pBluescript/MuSK­Ubmut (R. Herbst, unpublished data). These fragments reconstituted the coding sequence of MuSK 
extracellular and transmembrane domain. Instead of MuSK intracellular domain they comprised coding sequences for a 
FLAG­tag and wild­type or mutant ubiquitin.  
5.6.10 Transformation of Competent Bacteria  
Background Information:  
Bacteria were transformed in order to select and amplify successfully ligated plasmids after cloning 
or to gain fresh cells for amplification of already purified plasmid. In the first case competent bacteria 
were transfected with the ligation mix, which in general contained functional plasmids in a rather low 
concentration. Therefore it was important to yield optimal transformation efficiency. For 
transformation with already purified plasmid plasmid solutions of high concentration were used. 
Thus transformation efficiency was less essential and individual incubation times were shortened and 
steps were left out as indicated. 
Protocol:  
Competent E.coli were thawn on ice. 100 µL competent bacteria and 20 µL 5 x KCM were mixed in an 
Eppendorf tube. If bacteria were transformed with freshly ligated plasmid the total volume of ligation 
mix was added. If bacteria were transfected with purified plasmid in order to gain fresh cells for 
HA­MusK­Ubwt 
EheI 
EheI 
XbaI 
XbaI 
MuSK 390-1554 bp 
HA­MusK­Ubmut 
EheI 
EheI 
XbaI 
SpeI 
MuSK 390-1554 bp 
…CMV­Promoter 
…HA­tag 
…FLAG­tag 
…ubiquitin wt 
…ubiquitin mut (K48R, ΔGG) 
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plasmid amplification, ~300 ng ­ 2 µg DNA of plasmid preparation were added. The transfection 
mixture was adjusted to 200µL with sterile ddH2O, gently mixed and incubated on ice for 30 min. 
(15 min of incubation were sufficient for purified plasmid). E.coli were heat­shocked by incubation at 
42°C for 2 min and put back on ice briefly. 900 µL LB­medium w/o selective antibiotics were added 
and the cells were allowed to regenerate at 37°C for 30 min (15 min for purified plasmid). In case the 
transformation was performed with a ligation mix the bacteria were pelleted via centrifugation at 
16,100 rcf in a table­top centrifuge, LB­medium was removed apart from ~100 µL, in which bacteria 
were resuspended. This suspension was plated on LB­plates containing the selective antibiotic 
corresponding to the resistance conferred by the transfected plasmid. If purified plasmid was 
transfected bacteria were not pelleted. 100 ­ 200 µL of transfection mix diluted in non­selective LB­
medium were directly plated on selective LB dishes after 15 min of regeneration.  
Table 37| 5 x KCM Buffer 
Reagent  Concentration  
KCl 0.5 M  
CaCl2  0.15 M  
MgCl2  0.25 M  
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6 Abbreviations  
AA  acrylamide  
aa amino acid(s) 
Ab antibody 
Ach acetylcholine 
AchR acetylcholine receptor 
AchRα AchR subunit α 
AchRβ AchR subunit β 
AchRγ AchR subunit γ 
AchRδ AchR subunit δ 
AChRε AChR subunit ε 
ADP adenosine diphosphate 
ARF6 ADP­ribosylation factor 6 
Asn asparagine 
ATP adenosine triphosphate 
BBS  BES­buffered saline  
BES N,N­Bis(2­hydroxyethyl)taurine 
 
N,N­Bis(2­hydroxyethyl)­2­aminoethanesulfonic acid 
BSA bovine serum albumine 
Cdc42 cell division control protein 42 
CME clathrin­mediated endocytosis 
CMS congenital myasthenic syndrome(s) 
D­box destruction­box 
ddH2O double­distilled water  
dH2O  distilled water  
Dok7 docking protein­7 
DUB de­ubiquitinating enzyme 
E# embryonic day # 
E1 ubiqutin activating enzyme  
E2 ubiquitin­conjugating enzyme  
E3 ubiquitin ligase  
EGF epidermal growth factor 
EGFP  enhanced green fluorescent protein  
EGFR  epidermal growth factor receptor 
GAP GTPase­activating protein  
GDP guanosine diphosphate 
GEF GDP/ GTP exchange factor 
GTP guanosine triphosphate 
h hour(s) 
IB immunoblot 
Ig immunoglobulin 
IgG immunoglobulin G 
IP immunoprecicipation 
IRK insulin receptor kinase  
JM juxtamembrane 
K lysine 
61 
kDa kiloDalton 
LDLR low­density lipoprotein receptor 
LRP4 low­density lipoprotein receptor ­ related protein 4 
lrp4 lrp4 gene 
Lys lysine 
MG myasthenia gravis 
MG132 Z­Leu­Leu­Leu­al, Cbz­leu­leu­leucinal 
min minute(s) 
ms mouse 
MuSK muscle­specific kinase 
MuSK MuSK gene 
MVBs multivesicular bodies 
NMJ neuromuscular junction 
NMS neuromuscular synapse 
NPXY Asn­Pro­X­Tyr  
NSF N­ethylmaleimide sensitive fusion protein 
o/n over night 
P# postnatal day # 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate­buffered saline  
PCR  polymerase chain reaction  
PD pull­down 
PDGF platelet­derived growth factor 
PDGFR platelet­derived growth factor receptor 
PDZRN3 PDZ domain containing RING finger 3 
PEST sequences  proline­glutamate­serine­threonine­rich sequences 
PFA  paraformaldehyde  
PH pleckstrin­homology 
PPi inorganic diphosphate 
Pro proline 
PTB phosphotyrosine­binding 
pTyr phosphorylated tyrosine 
Rab Ras­related in brain 
RATL rapsyn­associated transmembrane linker protein 
RIPA buffer radioimmunoprecipitation assay buffer 
rbt rabbit 
RTK receptor tyrosine kinase 
SBP strepavidin­binding protein  
SDS sodium dodecyl sulfate 
sec second(s) 
SH2 Src homology 2 
Stim stimulation 
TBS­T Tris­buffered saline + Tween 
TF transfection 
TK tyrosine kinase 
TM transmembrane 
Tyr tyrosine 
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Ub ubiquitine 
UBD ubiquitin binding domain 
UIM ubiquitin­interaction motif 
UT untransfected 
X optional amino acid residue 
x times 
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8.2 Zusammenfassung  
Die  Rezeptor­Tyrosin­Kinase  MuSK  (muscle­specific  kinase)  ist  ein  Muskel­spezifisches 
Transmembranprotein  und  essentiell  für  die  Bildung  der  Neuromuskulären  Synapse  an  der 
Kontaktstelle von Motorneuron und Muskel.  
MuSK wird durch das Proteoglykan Agrin aktiviert, ein Protein, das an Nervenendigungen sekretiert 
wird.  Aktiviertes  MuSK  auto­phosphoryliert  and  stimuliert  die  Aggregation  von  Acetylcholin­
Rezeptoren  (AChRs)  in  dem  der  Nervenendigung  gegenüberliegenden  Bereich  der  Muskelzell­
Membran.  Dies  führt  zur  Ausbildung  eines  postsynaptischen  Apparates.  Um  diese  Prozesse  zu 
koordinieren  sind  komplexe  Signalmechanismen  erforderlich,  welche  in  den  vergangenen 
Jahrzehnten  intensiv  studiert  wurden.  Zahlreiche  weitere  Proteine,  die  an  der  Bildung  der 
Neuromuskulären Synapse beteiligt sind, wie LRP4, Dok7 und Tid1, wurden mittlerweile identifiziert 
und ihre Interaktion mit MuSK wurde erforscht. Dennoch sind die Kenntnisse über die Agrin­MuSK­
Signalkaskade unvollständig.  
Es wurde berichtet, das Aktivierungs­abhängige Endozytose von MuSK für die Aggregation von AChR 
erforderlich  ist.  Darauffolgende  Modifikation  von  MuSK  durch  Ubiquitinylierung  könnte  den 
intrazellulären  Transport  der  Kinase  regulieren.  Diese  Diplomarbeit  konzentrierte  sich  auf  darauf, 
nicht­Muskel Zellsysteme zu etablieren, in welchen die beiden Prozesse, MuSK Endozytose und MuSK 
Ubiquitinylierung, untersucht werden können. Heterologe Zellsysteme sind einfacher zu handhaben 
als  Muskelzellsysteme  und  erlauben  es,  bestimmte  Komponenten  der  Agrin­MuSK  Signalkaskade 
unabhängig von anderen Muskel­spezifischen Proteinen zu exprimieren und zu untersuchen.  
Ein Ziel dieser Arbeit war, ein Modellsystem zu erschaffen, in welchem heterolog­exprimiertes MuSK 
zu  einem  definierten  Zeitpunkt  aktiviert  werden  kann.  Es  wurde  getestet,  ob  die  Kinase  durch 
Dimerisierung mittels Antikörpern zu stimulieren  ist. Ebenso wurde versucht, MuSK mit dem Agrin­
Rezeptor LRP4 zu ko­exprimieren und mit Agrin zu aktivieren. Leider erzielten beide beschriebenen 
Methoden keine detektierbare Aktivierung. Daher wurde eine konstitutiv inaktive, unphosphorylierte 
und  eine  konstitutiv  aktive,  phosphorylierte  MuSK­Mutante  entsprechend  der  experimentellen 
Anforderungen modifiziert. Internalisierungsstudien mit diesen zwei Mutanten legten nahe, dass der 
Phosphorylierungszustand von MuSK keine Auswirkung auf deren Endozytose und den intrazellulären 
Transport hat.  
Um den Effekt von MuSK­Ubiquitinierung auf die Internalisierung der Kinase zu untersuchen, wurden 
HA­markierte  MuSK­Ubiquitin  Chimären  HA­MuSK­Ubwt  und  HA­MuSK­Ubmut  kloniert.  Es  wurde 
gezeigt, dass HA­MuSK­Ubwt, welches die extrazelluläre und die Transmembrandomäne fusioniert an 
Wildtyp­Ubiquitin  enthält,  in COS­7  Zellen polyubiquitinyliert wird. HA­MuSK­Ubmut, welches  zwei 
Mutationen  im  Ubiquitin­Teil  enthält,  wird  großteils  mittels  Anhängen  eines  einzelnen  Ubiquitin­
Moleküls modifiziert  oder bleibt unmodifiziert.  Es wurde  festgestellt,  dass MuSK­Ubiquitinylierung, 
ähnlich  wie  der  Phosphorylierungszustand,  keinen  signifikanten  Einfluss  auf  seine  Internalisierung 
und den Transport innerhalb der Zelle hat.  
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8.3 Abstract  
The  receptor  tyrosine  kinase  MuSK  (muscle­specific  kinase)  is  a  muscle­specific,  transmembrane 
protein  that  is  essential  for  the  formation of  the neuromuscular  junction at  the  site of  contact  of 
motor neuron and muscle.  
MuSK is activated via the proteoglycan agrin, a soluble protein secreted by nerve terminals. Activated 
MuSK autophosphorylates and stimulates aggregation of acetylcholine receptors (AChRs) in the area 
of  the  muscle  cell  membrane  that  opposes  the  nerve  terminal.  Consequently  a  postsynaptic 
apparatus is established. To coordinate these processes complex signaling mechanisms are required, 
which have been studied extensively in the past decades. Numerous additional proteins involved in 
neuromuscular  junction  formation  like  LRP4,  Dok7  and  Tid1  have  been  identified  and  their 
interaction with MuSK has been investigated. However, the knowledge about agrin­MuSK­signaling is 
still incomplete.  
Activation­dependent  endocytosis  of MuSK  has  been  reported  to  be  required  for  AChR  clustering. 
Subsequent  modification  of  MuSK  by  ubiquitination  might  control  intracellular  trafficking  of  the 
kinase.  This  diploma  thesis  focused  on  the  establishment  of  non­muscle  cell  systems  for  the 
investigation  of  the  two  processes, MuSK  endocytosis  and MuSK  ubiquitination. Heterologous  cell 
systems  are  easier  to  handle  than  muscle  cell  systems  and  allow  the  selective  expression  and 
characterization of distinct components of the agrin­MuSK­signaling cascade independent from other 
muscle­specific proteins.  
Initially,  the goal was to  create a model  system,  in which heterologously expressed MuSK could be 
activated at a defined time point. Stimulation by clustering with antibodies was  tested.  It was also 
tried to co­express MuSK with the agrin­receptor LRP4 and activate it with agrin. Unfortunately the 
respective  methods  did  not  result  in  detectable  induction.  Hence,  constitutively  inactive, 
unphosphorylated  and  active,  phosphorylated  MuSK  mutants  were  modified  according  to  the 
experimental  requirements.  Internalization  studies  with  these  two  mutants  suggested  that  the 
phosphorylation level of MuSK has no effect on its endocytosis and intracellular trafficking.  
To  study  the effect of  ubiquitination on MuSK  internalization, HA­tagged MuSK­ubiquitin  chimeras 
HA­MuSK­Ubwt and HA­MuSK­Ubmut were created. HA­MuSK­Ubwt comprising the extracellular and 
transmembrane domain  of MuSK  fused  to wild­type ubiquitin, was  shown  to be polyubiquitinated 
upon expression in COS­7 cells. HA­MuSK­Ubmut contains two mutations in the ubiquitin portion and 
is  rather modified  by  addition  of  a  single  ubiquitin molecule  or  not modified  at  all.  But  similar  to 
phosphorylation  levels,  the  extent  of  ubiquitination  was  found  not  to  significantly  influence 
internalization and protein targeting.  
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Juli 2006 einmonatiges Ferialpraktikum in einem Labor der Böhringer Ingelheim Austria 
GmbH in Wien 
 Fokus: Klonierung und Plasmid­Präparation 
  
seit Okt. 2005 Studium an der Universität Wien, Studienzweig Molekulare Biologie 
  
  
Juni 2005 AHS­Matura (mit ausgezeichnetem Erfolg) am Bundesgymnasium 
Diefenbachgasse 
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1997­2005:  Bundesgymnasium Diefenbachgasse, Wien XV, Zweig: Sprachliches Gymnasium 
 
1993­1997:  Volksschule Maurer Lange Gasse, Wien XXIII 
 
Sprachen: 
 
Englisch:  Sehr gut  
2004: Schulsprachreise nach Dublin/ Irland 
 
Französisch:  Gut  
2003: 2­wöchiger Sprachkurs in Cannes/ Frankreich 
 
Spanisch:  Grundkenntnisse 
 
Sonstiges: 
 
EDV:  erfolgreiche Absolvierung des Europäischen Computer­Führerscheines (ECDL) 
 
Hobbies:  
 
Musik  
Zeichnen & Grafik 
Sport (Ski, Snowboard, Eislaufen, Tennis, Radfahren, u. a.)  
Sprachen 
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8.5 Curriculum Vitae 
 
Personal Data: 
 
Name: Marlies Schlauf 
Address:  Rielgasse 41, 1230 Vienna 
Mobile Phone:  0664/7313 0905 
E­mail:  Schlauf@gmx.at 
 
Birthday:  June 11th 1987 
Birthplace:  Vienna 
Citizenship:  Austria 
Marital Status: single 
 
Education: 
 
January 2010 – 
January 2011 
diploma thesis in the group of Ruth Herbst, Section of Synapse Formation, 
Center for Brain Research, Medical University of Vienna  
focus: endocytosis of muscle­specific kinase and its role in neuromuscular 
junction formation  
  
December 2009 practical training of one month in the group of Javier Martinez, IMBA, Vienna  
focus: RNAi biology  
  
August­October 
2009 
practical training of three months in the group of Hartmut Beug, IMP, Vienna  
focus: properties of the lysosomal protein CREG and its role in EMT  
  
February 2009 practical training of one month in the group of Roland Foisner, Biocenter 
Bohrgasse, University of Vienna  
focus: expression levels of cell nucleus­localized protein LAP2alpha in mouse 
tissues and organs  
  
September 2008 practical training of one month in the group of Ferdinand Steinböck, Cancer 
Research Institute, Medical University of Vienna  
focus: analysis of the protective effects of a substance against chemical 
mutagenesis in yeast  
  
July 2006 practical training of one month in a laboratory of Boehringer Ingelheim Austria 
GmbH, Vienna 
  
since Oct. 2005 studies at the University of Vienna, branch: Molecular Biology 
  
June 2005 final exams at grammar school Diefenbachgasse, Vienna XV  
  
1997­2005:  grammar school Diefenbachgasse, Vienna XV; branch: Sprachliches Gymnasium 
(6 years French, 4 years Latin) 
 
 
Languages: 
 
English:  very good  
2004: language course (1 week) in Dublin/ Ireland 
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French:  good  
2003: language course (2 weeks) in Cannes/ France 
 
Spanish:  basic knowledge 
 
Other: 
 
EDV:  ECDL (European Computer Driving License) 
 
Hobbies:  
 
music  
drawing & graphic design 
sports (ski, snowboard, ice skating, tennis, cycling, etc.)  
languages 
 
 
 
